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1.1 Down syndrome and Alzheimer’s disease 
Aneuploidy is a genetic alteration due to an abnormal number of copies of a 
genomic region. The trisomy, complete or partial, is the most common aneuploidy 
of the chromosome 21 (Chr 21) and is the unique autosomal trisomy to produce a 
viable and functional human. John Langdon Down described this condition in 1862 
but only after 1932, it became clear that it was a consequence of a chromosomal 
abnormality. Trisomy of Chr 21, commonly known as Down syndrome (DS), is 
the most prevailing genetic cause of intellectual disability with an incidence of 
1:700 births. In the last decade, DS neuropathology has become an attractive field 
of research for several reasons: i) it can be regarded as a human model of 
accelerated aging; ii) it allows correlation between genetic defects and pathological 
phenotypes; iii) it allows correlation among neurogenesis defects, brain 
development abnormalities and cognitive decline. 
Complete triplication of the entire Chr 21 is not necessary to produce the clinical 
phenotype of DS individuals, indeed the triplication of just a portion of the distal 
long arm, described as DS critical region (DSCR), has been identified as sufficient 
[1]. The 95% of DS cases are caused by nondisjunction of chromosome in meiosis 
I, during the formation of gametes, that results in the presence of 24 chromosomes 
instead of the usual 23. The zygote obtained after fertilization of the gamete with 
extra Chr 21 and a gamete with a normal chromosomal set will have 47 
chromosomes instead of 46 [2]. While the 3.2% and 1.8% of residual DS cases are 
caused respectively by translocation and mosaicism [3]. Translocation refers to a 
partially or fully, additional copy of the Chr 21 attached to another chromosome 
and is present in every cell of the individual [2]. Instead in mosaic not all cells of 
the body carry an extra copy of Chr 21 and two different mechanisms have been 
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proposed to explain this phenomenon: i) the zygote has three copies of Chr 21 in 
every cell but during cell division, at least one cell line loses the extra copy of Chr 
21; ii) the zygote has two copies of Chr 21 but during the cell division one of the 
cells has a duplication of the Chr 21 obtaining so the copy extra [4]. 
The effects of the trisomy 21 vary widely from one individual to the other and not 
every DS subjects show all the phenotypic features caused by trisomy. Therefore 
it is conceivable to separate DS features in two types: i) those seen in all patients, 
as the cognitive decline or facial dysmorphology; and ii) those that have variable 
penetrance, such as the congenital heart defect that is observed in the 40% of the 
cases [5]. Furthermore, for the same phenotypic feature different grades of severity 
are also observed. In addition to the chromosomal abnormality on Chr 21 it is 
believed that additional environmental factors can play an important role in 
determining different phenotypes. Mainly, two hypotheses have been proposed to 
explain the phenotypic variability observed in trisomy 21 subjects: the “gene 
dosage hypothesis” and the “amplified developmental instability hypothesis”. The 
first hypothesis proposes that the overexpression of trisomic genes and their 
encoded proteins is directly responsible for the different phenotypical alterations 
in DS [6, 7]. The second hypothesis postulates that the presence of multiple 
phenotypes is caused by the effects of the overexpression of trisomic genes on 
dysomic genes leading to an imbalance in their expression [8]. So far, results 
obtained by the analysis of DS cases and the development of DS mouse models 
support both hypotheses. Therefore, the combination of these two hypothesis 
indicates a complex scenario where the consistently over or down-expression of a 
subset of dosage-sensitive genes lead to different phenotypic features. The 
pathology of DS is commonly accompanied by the alteration of nervous, 
respiratory, cardiovascular, gastrointestinal, hematologic, immune, endocrine, 
musculoskeletal, renal and genitourinary systems. Clinical features documented in 
DS subjects are microcephaly, craniofacial abnormalities, neuromotor 
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dysfunction, accelerated aging, cognitive and language defects, impaired 
mitochondrial function, increased oxidative damage and accumulation of 
damaged/misfolded protein aggregates. Some of the most consistent and striking 
alterations in DS involve the brain, which demonstrates reduced neuronal content, 
reduced frontal lobe volume and narrowed superior temporal gyrus. DS 
individuals, after the age of 40, develop a type of dementia that closely resembles 
that of Alzheimer’s disease (AD), the most common cause of dementia in older 
people, with deposition of senile plaques containing amyloid beta-peptide (Aβ) 
and neurofibrillary tangles (NFTs) composed of hyperphoshorylated tau and also 
cholinergic and serotonergic reduction [6]. Because AD is virtually inevitable in 
DS subjects the DS neuropathology can be considered a “natural model” of early 
AD and could contribute to understanding the overlapping mechanisms that lead 
to the neuropathophysiological progression of AD. The deposition of Aβ plaques 
is the most prominent and detrimental neuropathological change in AD brain and 
occur in cortical regions that are important in acquiring, storing and retrieving 
information. These regions include temporal lobe structures, such as the 
hippocampus, as well as frontal and parietal regions. Patients with AD are 
characterized by deterioration in control, thought, memory, language skills and 
personality changes associated with inappropriate or psychotic behaviors causing 
the decline in the ability to carry out daily activities [9]. Characteristic features in 
AD brain are weakening of synaptic networks, neuronal loss and increase of brain 
atrophy [10]. Aβ and tau lesions affect several brain regions in DS, including 
prefrontal cortex, hippocampus, basal ganglia, thalamus, hypothalamus and 
midbrain and are believed to underlie the development of cognitive decline and 
dementia. However, although the depositions of Aβ plaques have been observed 
in fetus and young DS individuals [11, 12], signs of dementia are clearly 
manifested many years later.  
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Inflammation and oxidative stress (OS) are known to occur in the brains of both 
AD and DS patients in response to the presence of Aβ plaques and NFTs [6, 13] 
and several studies demonstrated the involvement of OS and inflammation in 
accelerated senescence. In addition to OS and inflammation, also brain insulin 
resistance (BIR), described as an inadequate response to insulin, is considered one 
of the major events for the progression of AD-like pathology. Interestingly the 
evaluation of insulin signaling in DS brain has revealed the presence of insulin 
resistance similar to AD patients [14]. It is hypothesized a link between OS and 
BIR where increased OS leads to the reduction of both insulin secretion and 
sensitivity [15], in turn defective insulin signaling makes neurons more vulnerable 
to oxidative damage [16, 17]. Therefore, it is believed that these defects (OS, 
inflammation and BIR) could contribute to the severity of AD and act as potential 
accelerators in the progression of AD in DS subjects (Fig. 1). The identification 
and characterization of the genes and proteins Chr 21-encoded is crucial to 
understand the mechanisms through which the chromosomal abnormality could 
contribute to the development of AD in DS people and could provide insights into 
the mechanisms that cause dementia in the general population. The entire sequence 
of human Chr 21 has been resolved in 233 coding genes, 299 long non-coding 
genes (Ensembl release 78) and 29 microRNAs (miRBase release 21) [18]. After 
investigation with Swiss-Prot and analysis with Gene Ontology Annotation the 207 
proteins Chr21-encoded: i) take part in 87 different biological processes and 11 
proteins are involved in signal transduction; ii) have 81 different molecular 
functions among which DNA binding and transcription factor activity are the most 
prevalent with 15 proteins; iii) are localized in 26 different cellular components, 
nucleus and the plasma membrane with 19 and 15 proteins respectively are the 
most predominant cellular localizations [5]. Interestingly, several genes mapped in 
the Chr 21, such as CuZn superoxide dismutase (Sod1), amyloid precursor protein 
(App), ETS proto-oncogene 2 transcription factor (Ets-2), S100 calcium binding 
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protein B (S100b), cystathionine-beta-synthase (Cbs), β-amyloid cleavage enzyme 
2 (Bace2) and BTB domain and CNC homolog 1 (Bach1), are known to be 
involved in processes associated with inflammation, OS and insulin signaling (Fig. 
1). Accordingly, the overexpression of these genes and their effect on disomic 
genes (as postulated by gene dosage hypothesis and by the amplified 
developmental instability hypothesis) can lead to impaired of specific processes 
underlying the onset of neuropathological hallmarks in DS individuals.  
 
 
Fig. 1. Link between inflammation, OS and insulin signaling in DS and AD pathology. Several genes Chr 21-




1.2 Oxidative stress 
Increased OS has been implicated into the development and progression of 
neurodegenerative diseases [19] and increasing number of studies have recently 
shown that it occurs in the brains of both AD and DS subjects. OS is caused by an 
imbalance in the redox state of the cell, either by overproduction of reactive 
oxygen and nitrogen species (ROS/RNS), or by decreased antioxidant response. 
The high lipid content of nervous tissue, together with the high aerobic metabolic 
activity, leaves the brain particularly susceptible to oxidative damage [20]. 
Accordingly, it has been reported a strong correlation between augmented OS and 
several cellular toxic processes during neurodegenerative diseases: increased 
levels of ROS make neurons more susceptible to apoptosis and may alter APP 
processing promoting intracellular accumulation of Aβ. ROS such as superoxide 
anion (O2−•), hydrogen peroxide (H2O2) and hydroxyl radical (HO•), are either 
radical or non-radical oxygen species generated as by-products of aerobic 
respiration and various other catabolic and anabolic processes [21]. The major 
source of free radicals is the mitochondrial oxidative phosphorylation pathway, in 
which electron leakage from the electron transport chain causes the formation of 
O2−• that, in turn, is converted by mitochondrial-resident SOD into H2O2 and O2 
[22]. Once released, H2O2 is relatively stable and can diffuse through membrane. 
In the cytosol, H2O2 can be efficiently removed by antioxidant systems such as 
catalase (CAT), glutathione peroxidase (GPX) and thioredoxin peroxidase (Fig. 
2). Other than mitochondria, a number of cytosolic enzymes are able to generate 
ROS [23] in response to different environmental stimuli such as growth factors, 
inflammatory cytokines, ionizing radiation, chemotherapeutics, toxins and 
transition metals [24]. It is important to highlight that the ROS are not always 
harmful and their effects depend on their amount: i) at low concentration, ROS 
acts as signaling molecules and can activate many protective cellular apparatus 
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including cell growth, cell proliferation and cellular signal transduction [25]; ii) at 
high concentration, ROS acts as damaging by-products causing irreversible 
damage to the intracellular macromolecules (Fig. 2). Watson postulated also that 
several diseases including diabetes, dementias and cancer can be accelerated or 
even caused by failure to generate sufficient ROS [26].  
In fact, recent studies showed that insufficient levels of ROS could promote 
survival of malignant cells, due to failure to induce apoptosis, contributing to the 
tumor growth [27, 28]. Thus ROS, at least in some situations, can produce 
beneficial effects. Similarly, the antioxidants can be both harmful and healthy 
depending on the situation. For example, in premalignant stage, the antioxidants 
inhibiting ROS-induced DNA damage block the malignant transformation [29, 30] 
while in transformed cells inhibiting ROS-induced apoptosis lead to increased cell 
survival, proliferation and carcinogenesis [27, 28]. At physiological conditions, 
intracellular ROS are kept at low but measurable levels that result from the rate of 
production and the rate of scavenging by various antioxidants [31]. Considering 
that aging is the most important risk factor for neurodegenerative disorders, the 
progressive and irreversible accumulation of oxidative damage during aging can 
be a causative or at least a collateral factor in the development of neuropathologies. 
In parallel, the premature changes in the redox-responsive signaling cascades 
observed in DS subjects may have a similar or even greater impact than the 
accumulation of oxidative damage due to age on development of 
neurodegenerative disorders like AD pathology [25]. Proteomics studies, on AD 
and DS samples, identified several proteins, members of antioxidant systems, 
proteostasis networks, energy metabolism and maintenance of cell structure, to be 
specific targets of oxidative modifications. The main targets of ROS are proteins, 
lipids and nucleic acid so both loss of scavenging mechanisms and an increase in 





Fig. 2. ROS can be produced endo- or exogenously. The level of ROS is regulated by antioxidants defense 
mechanisms. Low levels of ROS production are required to maintain physiological functions, including: 
proliferation, signal transduction and cell growth. Under normal conditions, antioxidant defense mechanisms 
decrease excess ROS and maintain cellular homeostasis. However, overproduction of ROS generates OS, 





Protein oxidative modification. The proteins can be oxidized by direct ROS 
attack, by secondary oxidation products, such as the reactive aldehyde formed as 
final by-products of lipid peroxidation, or by glycoxidation reactions. The 
carbonylation is one of the most common oxidative post-translational 
modifications (PTMs) and often forms reactive aldehydes or ketones. Oxidation 
is, in the majority of cases, a non-reversible phenomenon that could alter the three-
dimensional conformation of peptides resulting in a loss or, in a few cases, a gain 
of function. In addition, protein oxidation could affect different processes 
including protein turnover, cell signaling, increased susceptibility to proteolysis 
and fragmentation enhancing the formation of protein aggregates often toxic to 
cells if allowed to accumulate [32-35]. The OS-associated irreversible damage to 
proteins seems to be involved in physiological aging and neurological 
degeneration [34]. Protein carbonyl groups are generated by direct oxidation of 
several aminoacid side chain, backbone fragmentation, α-carbon hydrogen 
extraction and Michael addition reactions of His, Lys and Cys residues with 
products of lipid peroxidation. Protein carbonyls also are produced by 
glycation/glycoxidation of Lys amino groups, forming advanced glycation end 
products (AGEs). All aminoacid residues can be attacked by ROS, but Met and 
Cys residues are particularly sensitive. In the case of Met, low levels of ROS lead 
to formation of Met sulfoxide (MeSOX) that in turn can be reduced by MeSOX 
reductases. In addition, the oxidation of sulfhydryl groups, often resulting in the 
formation of intra- or intermolecular disulphides, is reduced by disulfide 
reductases/isomerases. Since these two oxidative modifications can be 
enzymatically restored, in mammalian cells, it is likely they play a key regulatory 
role and sense the cells to changes in the redox environment. Indeed, a number of 
signaling pathways, such as JNK, p38 mitogen-activated protein kinases (MAPK), 
are strongly responsive to redox regulation. However, the interplay between 
individual redox-sensitive signaling proteins to redox-regulated processes in vivo 
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is quite complex. Lipid peroxidation is another source of free radicals, which 
directly damages membranes and generates a number of secondary products 
responsible for extensive cellular damage. The free radical attack to polynsatured 
fatty acid (PUFAs) leads to the formation of highly reactive electrophilic 
aldehydes, including malondialdehyde (MDA), 4-hydroxy-2-nonenal (HNE), the 
most abundant products and 2-propenal (Acrolein) the most reactive. The 
peroxidation of membrane lipids can result in increased membrane rigidity, 
decreased activity of membrane-bound enzymes (e.g. sodium pump), impairment 
of membrane receptors and altered permeability [21]. In addition, radicals also can 
directly attack membrane proteins and induce lipid–protein and protein–protein 
crosslinking, altering membrane integrity. Although the modulation of the proteins 
by HNE is mainly based their oxidative modification, there are also example of 
regulation of gene expression by targeting transcription factors such as NF-κB 
(nuclear factor-kappa B) and AP-1 (activator protein 1). HNE is also involved in 
the activation of the transcription factor Nrf2 (erythroid-devived 2-like 2), which 
transactivates the antioxidant responsive element (ARE). In this way, HNE 
stimulates the cellular antioxidant defenses through the upregulation of the 
expression of various genes such as heme oxygenase 1 (HO-1), aldehyde 
dehydrogenases (ALDH), glutathione S-transferase (GST). By its multiple impacts 
on protein regulation through transcriptional and post-translational modifications, 
HNE takes part in the maintenance of cellular homeostasis. However, higher levels 
of OS can lead to HNE accumulation, which could interfere with normal cellular 
signaling through the membrane damage and lead to the development of 
pathological conditions as it occurs in several neurodegenerative diseases [36]. 
Indeed, high levels of HNE deplete the cell of nucleophilic compounds that serve 
as antioxidants (glutathione, lipoic acid and thioredoxin) by covalently modifying 
proteins via Michael addition in a secondary protein carbonylation reaction [37]. 
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Protein bound and free reactive aldehydes are being investigated as potential 
markers of OS and disease progression in conditions ranging from 
neurodegeneration to brain infarction [38, 39]. 
 
Protein degrading systems can sustain cellular homeostasis by repairing or 
removing the oxidized products [40]. However, reduced activity of these 
mechanisms may render the cell incapable of efficiently removing oxidized 
biomolecules, resulting in their toxic accumulation. Two major pathways are 
responsible for the proteolysis of intracellular proteins, either for damage and self-
renewal: the ubiquitin-proteasome system (UPS) [41] and the autophagy-lysosome 
pathway (ALS) [42]. The UPS is located in the cytosol and the nucleus, it is 
responsible for the degradation of more than 70–80% of intracellular proteins and 
it is characterized by a high degree of specificity. In proteosomal degradation the 
protein substrates in order to be recognized undergo a covalent modification, 
known as ubiquitination, that requires the attachment of ubiquitin to the ε-amino 
group of an Lys residue of the protein substrate [43, 44]. In contrast, the 
degradation into the ALS seems to be non-specific [45] and includes: 
macroautophagy (indicated as autophagy), microautophagy and chaperone-
mediated autophagy (CMA). All three mechanisms share a common destiny of 
lysosomal degradation, but are mechanistically different one from another [46-48]. 
Experimental evidence suggests that failure of the UPS or ALS may contribute to 
neurodegeneration and that the up-regulation of these systems occurs in response 
to OS to remove oxidized proteins. However, in presence of high levels of free 
radicals, the degradation of oxidized proteins may be inefficient [49]. Indeed, 
oxidative modifications induce crosslinking/misfolding that may block the 
entrance of protein substrates in the proteolytic cavity of the proteasome [32]. In 
addition, oxidatively modified proteins may directly damage components of the 
degradation systems and ROS can damage lysosomal membranes [40].  
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Therefore, the accumulation of oxidatively modified proteins become a potential 
new source of free radicals. Taken together these considerations, it is clear that in 
addition to protein oxidation with accumulation of dysfunctional/damaged protein 
aggregates, the neurodegenerative processes also include the dysfunction of 
intracellular degradative systems such as UPS and ALS (Fig. 3).  
 
 
Fig. 3. Interplay between OS and protein degrading systems.  
Recently our group demonstrated that ubiquitincarboxy-hydroxyl lyase 1 (UCH-
L1), an enzyme with ubiquitin ligase/hydrolase activity, is a target of oxidative 
damage in DS brains, with a reduction of its enzymatic activity [50]. In this study, 
redox proteomics approach was used to analyze the frontal cortex from DS subjects 
under the age of 40 compared with age-matched controls and proteins found to be 
increasingly carbonylated were identified. Thus we observed an increased 
carbonylation levels of UCH-L1 with 2.12-fold associated to the reduction, about 
30%, of UCH-L1 enzyme activity in DS subjects compared with controls. 
Therefore, we suggested that the oxidative modifications causing irreversible 
alteration in the conformation and/or enzymatic activity of UCH-L1 result in 
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deleterious effects by impaired proteasome proteolytic system with accumulation 
of damaged proteins and formation of protein aggregates. Interestingly, a defective 
protein ubiquitination could result in reduced intracellular protein degradation, 
also in the presence of adequate proteasome activity. Therefore, the aberrant 
ubiquitin hydrolase and/or ligase activity, as result of UCH-L1 oxidative 
modifications, might lead to dysfunction of the neuronal 
ubiquitination/deubiquitination machinery, causing synaptic deterioration and 
neuronal degeneration in DS as well as demonstrated in AD brains [51-53].  
Thus, we hypnotize that these mechanisms may play a crucial role in the 
development of Alzheimer-like dementia in DS population. The impairment of 
autophagy has been largely implicated in AD neurodegeneration [54] and several 
studies suggested that it is likely to be caused by the hyperactivation of the 
mammalian target of rapamycin (mTOR) [55-57]. mTOR is a serine/threonine 
protein kinase that acts as regulator of autophagy because directly involved in the 
initiation step of this process by regulating the formation of the phagophore [48]. 
Indeed, autophagy involves several autophagy related proteins (Atg) that 
coordinate vesicle formation in three different steps: initiation, elongation and 
maturation. The initiation step is triggered in response to starvation by inhibition 
of mTOR that leads to the activation of the ULK1 kinase complex which comprises 
ULK1/Atg1-Atg13-FIP200/Atg17-Atg101 and causes the activation of another 
complex that comprises (among other proteins) PI3K, Vps34 and the protein 
Beclin-1 (Fig. 4). The later steps of autophagy the elongation and the closure of 
the autophagosome are dependent on the activity of the LC3-conjugation system. 
Consequently, the autophagosome matures by fusing with an endosome and/or 
lysosome, thus forming an autophago-lysosome. Therefore in physiological 
conditions mTOR, by inhibiting ULK1 complex, suppresses the phagophore 
formation that is essential for autophagy induction [58]. In addition, several studies 
suggested a link between mTOR signaling and Aβ and tau neuropathology [59-
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62]. Therefore it has been hypothesized that a sustained activation of mTOR can 
impact directly the AD pathology because it regulates the processing and clearance 
of Aβ and tau aggregates.  
 
 




DNA damage and mitochondrial dysfunction. The ROS are able to cause 
structural alterations in DNA: OH• generates a multiplicity of products from all 
four DNA bases while O2 selectively attacks the guanine. The most commonly 
product of oxidative DNA damage is 8-hydroxyguanine (8-OHG). If damage is 
not properly repaired, it generates a mutation caused by the incorrect pairing during 
replication. The mitochondrial dysfunction is a crucial event for neurodegeneration 
because of the central role of mitochondria in many cell functions such as ATP 
generation, intracellular Ca2+ homeostasis, ROS formation and apoptosis. The 
neurons, accordingly with their high-energy demand, are sensitive to 
mitochondrial dysfunction and the role of mitochondrial dysfunction in AD is well 
established [63, 64]. Altered mitochondrial activity has been reported also in DS 
fibroblasts [65] and both DS neurons and DS astrocytes display an abnormal 
pattern of protein processing consistent with chronic energy deficits [66]. A link 
between OS and mitochondrial dysfunction is observed. Both DS and AD neurons 
are vulnerable to increased ROS levels and decreased mitochondrial function 
indicating that these events may participate in a self-sustaining vicious cycle 




1.2.1 Oxidative stress and trisomy 21  
Several studies have recently associated the increased OS that occur in DS 
pathogenesis at the deregulation of triplicated genes that, directly or indirectly, 
participate to create an imbalance between production and clearance of ROS. 
Among these, the most relevant OS-inducers are Sod1, App, Bace2, Ets-2, S100b 
and Bach1. One interesting aspect of this complex process is that ROS can be 
generated during the early phases of protein self-aggregation [67] and considering 
that ROS-damage induces protein aggregation, these events may participate in a 
self-sustaining vicious cycle. Therefore, we suggest that an increased OS can be 
due not only to the overproduction of ROS and/or by decreased antioxidant defense 
system but also from the accumulation of protein oxidative damage in the presence 
of reduced degradative protein system. 
 
SOD1 is an antioxidant enzyme that catalyzes the dismutation of O2−•, a by-
product of oxidative metabolism, to produce H2O2 and O2. Therefore, SOD1 
protects the cells against ROS and consequently it is thought as a neuroprotective 
agent but, as demonstrated by Shin et al, transgenic mice overexpressing wild-type 
human SOD1 (Tg-SOD1) displayed mitochondrial alterations and learning and 
memory deficits [68]. In addition to the anti-oxidation effects, SOD1 generates 
H2O2, that is a potential source of oxidative damage, which turn is neutralized with 
O2 by CAT and by GPX in H2O [69]. DS subjects present in erythrocytes, B and 
T lymphocytes, and in fibroblasts, levels of SOD1 approximately 50% higher than 
normal subjects, while both CAT and GPX are generally expressed at lower levels 
in DS subjects compared with normal subjects [20]. The increase of SOD1 
expression and low levels of CAT and GPX produces an imbalance between SOD1 
activity and GPX/CAT activity which can results in the accumulation of H2O2 (Fig. 
5). In turn, the accumulation of H2O2, in the presence of Fe(II) or Cu(I), leads to 
hydroxyl radical formation, which damages membrane lipids, proteins and nucleic 
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acids. However, as also shown by a proteomics study from Gulesserian et al. [70] 
increased OS in fetal DS brain is not only a consequence of SOD1 overexpression, 




Fig. 5. Imbalance activity between SOD1 and GPX/CAT can result in H2O2 accumulation resulting in 




APP is the precursor protein of Aβ, the major component of plaques, found in the 
brain of AD patients and in middle-aged individuals DS. APP is a transmembrane 
protein and is differentially cleaved by enzymes called secretases. Three secretases 
are responsible for the cleavage of APP. Aβ is generated by the sequential 
proteolytic processing of APP throughout the β-secretase β-site amyloid precursor 
protein–cleaving enzyme 1 (BACE-1) and γ-secretase a protein complex with 
Presenilin. The γ-secretase can generate several isoforms of Aβ with different 
length: Aβ40 and Aβ42 are the most common isoforms. Instead the cleavage of 
APP by primarily α-secretase and subsequently γ-secretase results in the formation 
of a peptide called p3. Aβ soluble peptides spontaneously aggregate to form 
oligomers and fibrils that are subsequently deposited within the brain to form both 
diffuse and dense core amyloid plaques (Fig. 6). Accordingly with the gene-dosage 
effect, DS individuals show the overexpression of APP, which might lead to the 
increased production of Aβ [15-17]. APP has been considered as a probable OS-
inducer, indeed, as supposed by “AD amyloid hypothesis” and then demonstrated 
by experimental evidence, Aβ is toxic to cells because it induces the production of 
H2O2 and mitochondrial dysfunction [67, 71-74]. Indeed Aβ inserts into the bilayer 
acts as a catalytic producer of ROS, initiating the lipid peroxidation [73, 75] where 
a carbon centered radical is produced on a PUFA by the abstraction of an allylic 
hydrogen from sulfuranyl free radical on Met-35 of Aβ(1-42). Molecular oxygen, 
which lacks a dipole moment, diffuses into the lipid bilayer where it may react 
with the carbon centered radical to form a lipid peroxyl-radical [76, 77]. The lipid 
peroxyl-radical may then abstract an allylic hydrogen from an adjacent poly-
unsaturated lipid which propagates the chain reaction and forms a lipid 
hydroperoxide that may then undergo cleavage forming an array of possible 
reactive aldehydes such as F2-isoprostane, HNE and Acrolein. An imbalance 
between production, clearance and aggregation of peptides causes Aβ 
accumulation and this excess may be the initiating factor in AD. However, the 
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additional copy of App in DS does not typically cause substantial Aβ accumulation 
until the second or third decade of life, but the subtler Aβ changes occur in younger 
patients with the activation of endocytic uptake and recycling of Aβ. This lack of 
early Aβ accumulation may be due to App not becoming dosage sensitive until 
adulthood [78-80]. However, increased levels of soluble Aβ42 are found in ~50% 
of DS fetal brains [12], suggesting that App may be dosage sensitive during fetal 
development but that this change may not be sufficient to cause extensive Aβ 
deposition in the developing. It is important to highlight that App is not necessary 
for the development of DS phenotype, but its triplication can be necessary for the 
development of AD pathology in DS patients. This idea has been confirmed by the 
exceptional case DS of 78 year old with partial trisomy 21 that did not include the 
App gene, although of extremely advanced age without clinical or pathological 
evidence of AD [81].  
 




APP-cleaving 2 enzyme (BACE2) and the transcription factor ETS-2 have been 
suggested to modulate APP processing and Aβ generation. BACE2, homologous 
to BACE1, is a cleavage enzyme essential for processing of APP in Aβ 40 and 
Aβ42 (Fig. 6) [78, 82]. While ETS-2 is thought to trans-activate the APP promoter, 
leading to its overexpression. The presence of App, Est2 and Bace2 on Chr 21 and 
the resulting co-overexpression of these genes could reinforce the link between 
trisomy 21, OS and the development and progression of AD in DS [83]. 
 
S100B is an astroglial-derived Ca2+-binding protein that acts as neurotrophic factor 
on neurons and glial cells by modulating cell proliferation, differentiation and 
interaction with many immunological functions of the brain. In addition, it is 
involved in the regulation of energy metabolism by stimulating the enzymatic 
activity of fructose-1,6-bisphosphate aldolase and phosphoglucomutase [84]. The 
effects of S100B depend on its concentration: at nanomolar concentrations the 
neuroprotective effects prevail, while at micromolar concentrations 
neurodegenerative or apoptosis-inducing effects are observed [84, 85]. The 
neurotoxic actions of S100B could be due to the increased expression of nitric 
oxide synthase (NOS) with release of nitric oxide [86] and mobilization of calcium 
stored in neurons by stimulation of phosphoinositide hydrolysis by phospholipase 
C [87]. S100B is overexpressed in the brains of DS fetuses [88], and this 
overexpression continues throughout life [85].  
 
BACH 1 is a transcription repressor that plays an important role in the regulation 
of the expression of genes involved in the cell stress response. BACH1, under 
physiologic conditions, forms heterodimers with small Maf proteins (i.e., MafK, 
MafF and MafG), which bind the ARE of DNA thus inhibiting the expression of 
specific proteins. By contrast, increased OS levels suppress the function of 
BACH1 [89-91] by promoting BACH1 nuclear export and enhancing the 
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expression its genes target. When the intracellular heme levels increase, as under 
pro-oxidant condition, nuclear BACH1 binds heme and dissociates from the AREs 
thus allowing the expression of genes [92] such as: Quinone oxidoreductase-1 
(NQO1), glutathione S-transferase (GST), glutamate-cysteine ligase (GCL) and 
HO-1 (Fig. 7) [93]. HO-1 catalyzes the first and rate-limiting enzymatic step of 
heme degradation, producing equimolar amounts of carbon monoxide (CO), Fe(II) 
and biliverdin [94-96]. The biliverdin is latter converted into the powerful 
antioxidant bilirubin by biliverdin reductase A (BVR-A). BVR-A is also a 
Ser/Thr/Tyr kinase that interacts with members of the MAPK family, in particular 
the extracellular signal-regulated kinases 1/2 (ERK1/2) that once translocated into 
the nucleus regulates the expression of oxidative-stress responsive genes such as 
HO-1 or inducible nitric oxide synthase (iNOS) [97, 98]. The HO-1/BVR-A axis 
represents one of the main systems through which cells counteract/prevent OS-
induced intracellular damage [92, 99-102] and any imbalance of activity its 
elements would result in increased oxidative stress levels. The upregulation of 
Bach1, due to trisomy 21, can promote the lack of induction of antioxidant 





Fig. 7. Regulation of OH-1 by Bach1 and heme. BACH1 occupies ARE enhancers to repress transcription 
under normal conditions. An increase in heme levels, as under pro-oxidant condition, alleviates BACH1-
mediated repression through inhibition of its DNA-binding activity and subsequent nuclear export, making 
ARE available for activating Maf complexes including Nrf2. HO-1 catalyzes the first and rate-limiting 
enzymatic step of heme degradation, producing biliverdin which is then converted into the powerful 
antioxidant bilirubin by BVR-A. The upregulation of Bach1 due to trisomy 21 related could promote the lack 





Inflammation is known to occur in the brains of both AD and DS patients due to 
the presence of Aβ plaques and NFTs. Inflammation is a protective response to 
exogenous and endogenous stimuli, however exaggerated or prolonged 
inflammatory process can induce tissue damage. Although the role of the 
inflammation in the progression AD is well-established, it is poorly understood 
how inflammation may affect the pathology of DS and how genetic alteration in 
DS may alter the inflammatory response. The brain, once considered 
“immunologically privileged”, is now recognized to exhibit an almost complete 
spectrum of inflammatory responses. The primary immune effector cells of the 
brain are the microglial cells an ameboid-like cell that can be labeled 
immunocytochemically using macrophage cell surface markers [103, 104]. 
Microglial cells play a fundamental role in maintaining brain homeostasis by 
taking up cellular debris and protecting the brain from invading pathogens. 
Astrocytes and neurons also can contribute to the inflammatory response, although 
their contribution is considered lower than that of the microglia [105]. Microglial 
cells, like other tissue macrophages, respond to their local environment and so that 
cells located in different brain area can show distinct phenotypes [106]. In AD, 
activated microglia is highly localized to the area immediately surrounding an Aβ 
plaque or NFTs [107] and their number/size directly increases in proportion to 
plaque dimension [108-110]. Additionally, microglial cells at the periphery of Aβ 
deposits can also proliferate, allowing for the accumulation of these cells [111, 
112]. However, the role of the microglia during neurodegeneration is controversial 
because its activation could have both a beneficial effect, playing a neuroprotective 
role removing the abnormal protein deposits from AD brain, and a detrimental 
effect contributing to the neurotoxicity observed in AD. Most likely, both the 
effects occur in AD brain but at different pathology degree. Receptor complexes 
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located on the microglial cell surface allow to recognize fibrillar forms of Aβ and 
their activation initiates an intracellular signaling cascade that results in microglia 
activation through NF-κB mediated gene transcription [113-115]. In AD, many 
inflammatory cytokines and chemokines have been found to be increased, 
including interferon γ (IFNγ), Tumor necrosis factor α (TNFα), Interleukin 1β (IL-
1β) and Interleukin 6 (IL-6) [116-120]. IFNγ or TNFα stimulation in neurons 
increase the production of Aβ from APP while in microglial cells impair the ability 
to degrade Aβ [118]. The microglia exposure to fibrillary forms of Aβ has been 
demonstrated in vitro to provoke the synthesis and secretion of pro-inflammatory 
cytokines (including IL-1β, IL-6, TNFα), chemokines, ROS and RNS [116, 121-
125]. These studies support the idea that the inflammation might impact negatively 
the ability of microglial cells to take up Aβ deposits and suggest that the inhibition 
of inflammatory signaling can enhance Aβ clearance. Although the inflammation 
plays beneficial roles in pathogen removal, it can also be detrimental if the 
response is not downregulated. Thus, the CNS can suppress microglial activation 
through interactions between microglial and neurons or other glial cell types. For 
example, the interaction between the fractalkine receptor (CX3CR1) expressed on 
microglial cell surface and its ligand fractalkine (CX3CL1) expressed on neurons 
and astrocytes prevents microglia activation. It is thought that, due to loss of 
neurons, this ligand-receptor interaction is lost and can contributes to the activation 
of microglial cells during neurodegeneration [126]. Similarly, at CX3CR1 and 
CX3CL1, the interaction between CD200 receptor located on neurons and CD200 
ligand expressed on microglial cells also inhibits microglia-mediated inflammation 
and in vitro can attenuate Aβ-induced glial activation [127]. Interestingly both are 
reduced in the hippocampus and cortex of AD patients [128]. Also CD45, a 
microglia transmembrane protein-tyrosine phosphatase, plays a similar role and 
the interaction with its ligand, CD22, inhibits the production of pro-inflammatory 
cytokines by microglia in response to lipopolysaccharide [129]. CD22 is normally 
INTRODUCTION 
25 
secreted by neurons. In contrast, the interaction between CD40 receptor and its 
ligand promotes an inflammatory response leading to the production of TNFα and 
IL-1β [130]. In human AD brain the expression of CD40 and its ligand is increased 
around Aβ plaque [131, 132] while in AD mouse model deficient for CD40 ligand 
a marked reduction in Aβ load and microglial activation has been revealed [133]. 
These observations suggest that many mechanisms that act to ensure tight control 
of microglial activation are compromised in the AD brain which can promote the 




1.3.1 Inflammation and trisomy 21  
Given that Chr 21 contains critical genes involved in pro-inflammatory and anti-
inflammatory processes it is imaginable that the triplication of these inﬂammatory-
associated genes in DS causes a unique inﬂammatory environment that could 
promote and influence the development of clinical and neuropathological 
manifestations of AD. Therefore, the study of inﬂammation in DS could be useful 
to understand the role of these inﬂammatory pathways in neurodegenerative 
disorders. Among the inﬂammatory associated genes found on Chr 21 the most 
relevant in cytokines are: 
 
Cxadr that encodes for a protein called coxsackie virus and adenovirus receptor. 
In the heart, it induces stress-activated MAPK pathways that result in increased 
production of IFNγ, IL-12, IL- 1β, TNFα and IL-6 [134]. Therefore it is imaginable 
that in DS brain the overexpression of Cxadr could contribute both to increase the 
IL-1β levels and tangle formation by hyperphosphorylation of tau MAPK-p38-
dependent [135, 136]. 
 
Ifnra1, Ifnar2 and Ifngr2 that encode for interferon receptors IFNα1, IFNα2 and 
IFN-γ [137, 138]. Upon ligand binding they activate the signaling pathway leading 
to induction of IL-1β, TNFα, and IL-6 expression [139]. Their overexpression 
could make DS individuals hyper-responsive to IFN and therefore to contribute to 
the elevated inflammatory response both in the brain and systemically. 
 
Ripk4 that encode for a protein kinase involved in the signaling pathway for the 





Cbs that encodes for the cystathionine beta synthase [141] a cytosolic enzyme that 
catalyzes the desulfhydration of Cys for production of hydrogen sulfide an atypical 
cellular messenger [142, 143]. The effects of CBS depend on its concentration: at 
low levels appear to be anti-inflammatory, while high levels appear to intensify 
neuroinflammatory processes [144, 145]. 
 
Prmt2 that encodes for an enzyme that catalyzes the methylation of Arg. It has 
been shown that Arg methylation is necessary for regulation of the JAK/STAT 
signaling pathway which is key for the expression of IFNγ, IFNα IL-6 [146] and 
promotes the apoptosis by inhibition of NF-κB [147]. 
According to the systemic immune macrophage profiles it is possible to discern 
four distinct inﬂammatory states in response to a stimulus in 
microglial/macrophage cells: M1, M2a, M2b and M2c [148, 149]. 
M1state is induced by IFNγ and TNFα and is characterized by release of IL-1β, 
IL-6 and IL-12. M2a response is initiated by IL-4 and IL-13 and it is characterized 
by tissue remodeling factors FIZZ and YM1 as well as AG1 and mannose receptor 
C1(MRC1). M2b response has components of both M1 and M2a states. It is 
characterized by elevations of: M1 markers particularly IL-1β, TNF-a and IL-6 
and M2 marker including CD86. M2c response is stimulated by IL-10 and it is 
characterized by a series of markers that antagonize M1 signaling pathways.  
Since most of the Chr 21 genes are primarily associated with the M1 inﬂammatory 
response, it could hypnotize that M1 is the main glial activation state in the DS 
brain. Indeed the triplication of interferon receptors Ifnra1, Ifnar2 and Ifngr2 could 
enhance interferon signaling in DS and therefore increase the production of M1 
markers such as IL-1β, TNFα and IL-6 (Fig. 8). Wilcock et al. [150], examining 
the expression of the macrophage phenotypes markers in DS brain, observed a 
strong M2b response. This unexpected result would suggest that there might be 
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over-riding factors beyond the genetics of DS responsible of this phenotype (Fig. 
8). The analysis of such markers in AD brain demonstrated a broad heterogeneity 
in the neuroinflammatory state, indeed early AD stages show half of the cases with 
M1 phenotype and the other half with M2a response, while late AD stages show a 
more homogeneous neuroinflammatory state, with markers of M1, M2a, and M2c 
being elevated (Fig. 8). Interestingly, the M2b phenotype was never seen in the 
AD samples therefore this findings highlight distinct differences between the DS 
brain and AD brain and suggest that, neuroinflammation has unique features in the 
DS aging brain that could directly modulate responses to interventions that include 
immunotherapy or anti-inflammatories. 
 
 
Fig. 8. Inﬂammatory states in DS and AD brains. Although Chr 21 genes are primarily associated with the 
M1 inﬂammatory response in DS brain is observed a strong M2b response suggesting that there might be over-
riding factors beyond the genetics of DS responsible of this phenotype. Interestingly, the M2b phenotype was 
never seen in the AD samples. These findings highlight that DS aging brain shows a unique inﬂammatory 




1.3.2 Inflammation as accelerator of AD in DS: the cytokine cycle  
The discovery that in AD brain both microglia and astrocytes express excessive 
amounts of IL-1β and S100B opened the possibility that events in AD pathogenesis 
could be driven by cytokines. Interestingly in DS brains of fetuses, neonates and 
children prominent glial activation with excessive expression of both IL-1β and 
S100B has been observed compared with non-DS individuals of similar ages [88]. 
It is important to highlight that such changes occur years before the appearance of 
the senile plaques [151-153] indeed the substantial Aβ accumulation is not 
typically observed until the second or third decade of life. Thus, premature changes 
in these cytokines could render the DS brain more susceptible to AD pathogenesis 
promoting later the development of Aβ plaques and NFTs in DS. Several studies 
support the importance of these changes for the development of AD 
neuropathological anomalies in DS brain showing (Fig. 9): i) the capacity of both 
IL-1β and S100B to induce the synthesis of APP [154, 155]; ii) the capacity of IL-
1β to induce the synthesis of S100B [156]; iii) the induction of tau phosphorylation 
through IL-1β-induced activation of MAPKp-38 [157]; iv) the capacity of both 
APP and S100B to induce the overexpression of IL-1β [158, 159]. 
In this complex scenario the upregulation of trisomy 21-related genes such as App 
and S100b could be sufficient to promote IL-1β overexpression and favor the start 
and self-sustaining of this vicious cycle (Fig. 9) and explain why the levels of APP 
and S100B protein are greater than the expected from the 1.5-fold gene load. The 
lifelong overexpression of IL-1β, in DS brain, could promote neurodegenerative 
process not only by Aβ plaques and NFTs deposition but also promoting : i) the 
synthesis and the activity of acetylcholinesterase, favoring the breakdown of 
acetylcholine[160], an important neurotransmitter in learning and memory [161], 
which is known to be decreased in AD [162, 163]; ii) the decreases in the 
expression of synaptophysin [135], which is a hallmark of the synaptic loss in AD 
[164, 165]; iii) the direct toxic effect on cortical neurons [166], that may also 
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contribute to neurotoxicity plaque-associated in the promotion of microglial 
activation [167]. Taken together these reports suggest the existence of a positive 
feed-forward loop potentially chronic where IL-1β and S100B both induce 
microglial and astrocytic activation with overexpression of themselves, as well as 








1.3.3 Crosstalk between Oxidative Stress and Inflammation  
OS and inflammation are closely related processes and often are simultaneously 
found in many pathological conditions. It is important to note that OS can be 
induced by inflammation and vice-versa (Fig.10).  
 
 
Fig 10. Inflammation and OS work together creating a vicious cycle. 
In fact, inflammatory cells can release ROS/RNS promoting exaggerated OS 
[168], on the other hand, the ROS/RNS can initiate intracellular signaling cascade 
that enhances pro-inflammatory gene expression [169, 170]. Numerous studies 
support an interdependent relationship between inflammation and OS, as reviewed 
by Brasier and Castellani [171, 172]. Under pathological inflammatory conditions 
an increased generation of reactive species takes place as result of direct 
production by professional phagocytic cells or in response to proinflammatory 
cytokines by non-phagocytic cells [173, 174]. Recent finding suggests that the 
costimulation of TLRs produces OS with unbalance of pro-inflammatory and anti-
inflammatory cytokine production [175] (Fig 11): i) IFN𝛾 has been found to 
increase ROS production enhancing the expression of Duox2, a NADPH oxidase, 
through the TLR4-NF-kB pathway [173]; ii) IL-6 has been found to produce ROS 
increasing the expression of NADPH oxidase 4 (NOX4) as well as the NOX4 
overexpression has been found to enhance IL-6 production [174].  
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Through, the increased OS can induce inflammation (Fig 11): i) H2O2 can activate 
NF-kB inducing the inflammatory responses [169, 170]; ii) The ROS released from 
damaged mitochondria has been shown to activate NOD-like receptor protein 3 
(NLRP3) inflammasome an oligomeric molecular complex involved in the 
maturation of proinflammatory cytokines like IL-1β and IL-18 [176-178].Based 
on these observations it is possible to hypothesize the presence of a vicious cycle 
between mediators of inflammation and OS [179]. Thus, if OS appears as the early 
defect, inflammation will lastly evolve and will further exaggerate OS. 
Conversely, if inflammation is the primary abnormality, OS will develop its 
consequence and will further accentuate inflammation [179]. Therefore, 
identification of primary abnormality could be of great clinical importance, as the 








1.3.4 MicroRNA and Inflammation 
MicroRNA (miRNA) are a class of highly conserved small non-coding RNA 
molecules, approximately 22 nucleotides in length, involved in the regulation of 
gene expression by binding the 3’ untranslated region (3’-UTR) of target 
messenger RNAs (mRNAs). miRNAs act at post-transcriptional level promoting 
gene silencing through two distinct mechanisms sequence-dependent: i) cleavage 
of mRNAs with subsequent degradation or ii) translation inhibition of 
corresponding protein. Typically, a miRNA can bind to many targets and each 
target may be regulated by multiple miRNAs. Thus the miRNAs take part into 
many biological processes including differentiation, growth, homeostasis, stress 
responses and apoptosis. Increasing evidence supports also their involvement in 
brain development. Interestingly, compared with other organs, the brain has a 
particularly high percentage of tissue-specific and tissue-enriched miRNAs [180-
183]. Although it has been suggested that the altered expression or function of 
miRNAs could critically contribute to brain injury including neurodegenerative 
diseases the full scope of miRNA-mediated regulation of brain functions is largely 
unknown. Mature miRNAs are transcribed from longer RNA molecules, with a 
stem loop structure, called primary miRNA (pri-miRNA) by RNA polymerase II 
or RNA polymerase III. Within the nucleus the pri-miRNA is cleaved by the 
Drosha-DGCR8 complex into a smaller RNA molecule termed pre-miRNA, which 
is then actively transported to the cytoplasm by Exportin 5 in complex with Ran-
GTP. In the cytoplasm, the pre-miRNA is cleaved into mature miRNA with 3’ 
overhangs by the Dicer-TRBP complex and finally loaded onto the Argonaute 
protein (AGO) to form the RNA-induced silencing complex (RISC). The miRNA 
in the RISC complex functions as a guide binding the 3’-UTR of target mRNAs in 
sequence-dependent manner and the degree of the complementarity between the 
miRNA and mRNA determine the gene silencing mechanism: slicer-dependent 
mRNA degradation or slicer-independent translation inhibition [184]. The 
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miRNAs, controlling the expression of different genes, in convergent or divergent 
manner, may affect diverse cellular and metabolic pathways and therefore 
profoundly influence the cellular behavior. Altered expression of miRNAs has 
been shown to be responsible for inducing different disease phenotypes including 
cancer, metabolic disorders, immune disorders and neurological abnormalities. In 
addition, several miRNAs have been shown to play a critical role in the microglia-
mediated inflammatory response, such as miR-146a and miR-155. Both miR146a 
and miR155 are involved in the TLR-signaling, expressed in NF-kB-dependent 
manner and associated with IL-1β pathways [185]. Emerging evidence [186] 
shows that the IL-1β signaling is differentially modulated by overexpression of 
miR146a and miR155, which resulted in anti- or pro-inflammatory effects 
respectively (Fig. 12). miR-146a can modulate the TLR-signaling pathway by 
direct targeting of Interleukin-1 Receptor Associated Kinase-1 (IRAK1) and TNF 
receptor associated factor 6 ligase (TRAF6) [187-191], important components for 
activation of the TLRs signaling. miR146a blocks the TLR-signalling by 
suppressing NF-kB transcriptional activity and sequentially suppresses the 
production of type I IFNs, TNF, IL-1β, and IL-6 [188-190]. In contrast miR-155 
inhibits Src homology 2 domain-containing inositol-5 -phosphatase 1 (SHIP1), a 
negative regulator of TLR-signaling to enhance the inflammatory responses [192-
195]. SHIP1 negatively regulates TLR-signaling by inhibiting PI3K activation and 
suppressing ERK1/2, JNK and NF-kB pathways [196-198]. Both miR-146a and 
miR-155 seem to play a fundamental role in the microglial inflammatory profile. 
While miR-146a acts as a negative regulator of inflammation by suppressing NF-
kB transcriptional activity, miR-155 acts to potentiate the microglial-mediated pro-






Fig. 12. Positive and negative regulation of inflammation mediated by miRNA. miR-155 and miR146 are 
induced by proinflammatory stimuli such as TLR ligands, LPS and cytokines such as IL-1β and through the 
activation of proinflammatory transcription factors NF-kB. miR-146 is thought to negatively regulate TLR 
signaling through control of expression of key signaling intermediates IRAK-1 and TRAF-6. In contrast miR-





1.4 Insulin resistance in AD 
Epidemiological studies have shown that glucose intolerance and impairment of 
insulin secretion are associated with a higher risk to develop dementia [199-202]. 
Insulin is a peptide released from pancreatic β-cells under hyperglycemic 
conditions and is transported into the CNS across the blood brain barrier (BBB) by 
a saturable receptor-mediated process [203, 204]. A portion of the insulin is locally 
produced in the CNS as proved by the detection of c-peptide (which is an integral 
part of the pro-insulin molecule) and insulin mRNA in the brain [205].  
In the brain the activation of insulin signaling cascade does not induce a significant 
glucose uptake [206, 207] as it does in peripheral tissues, but, rather it modulates 
energy homeostasis, neuronal survival, longevity, learning and memory [208, 209] 
(Fig. 13). The binding of insulin to insulin receptor (IR) induces the 
autophosphorylation of specific Tyr residues on the β-subunit of the receptor with 
the consequent recruitment of the insulin receptor substrate-1 (IRS-1) [20, 210]. 
This latter, in turn, activates two main signaling pathways (Fig. 13): i) PI3K 
pathway, which is involved in the maintenance of synaptic plasticity and memory 
consolidation [211, 212]; ii) MAPK cascade that is responsible for the induction 
of the genes required for neuronal and synapse growth, maintenance and repair 
processes, as well as serving like a modulator of hippocampal synaptic plasticity 
that underlies learning and memory [213]. The alteration of all these processes are 
potentially implicated in the development of neurodegenerative defects. AD brain 
is characterized by defective insulin signaling and postmortem AD brain shows 
reduced sensitivity of IR, reduced expression of IR and Insulin-Like Growth Factor 
receptors (IGF-1R) and hypophosphorylation of IR and IRS-1 (Fig. 13). These 
abnormalities in AD brain are convincingly linked with a dysregulation of the 
insulin machinery and consistent with an inadequate response to insulin known as 
BIR. Although BIR is now widely accepted to be one of the major risk factors for 
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driving the progression of AD pathology, the mechanisms that underlie this 
process are not fully elucidated.  
 
 
Fig. 13. Mechanism(s) underlying insulin resistance. Under normal conditions binding of insulin to IR 
promotes IR activation through IR dimerization and autophosphorylation of specific Tyr residues. Stimulation 
of IR kinase activity is then followed by Tyr phosphorylation of a variety of endogenous substrates, including 
IRS-1. These events lead to the activation of multiple signaling pathways required for insulin's pleiotropic 
action, including: (i) PI3K) pathway and (ii) MAPK pathway. In the brain the activation of insulin signaling 
cascade does not induce a significant glucose uptake but, rather it modulates energy homeostasis, neuronal 
survival, longevity, learning and memory. AD brain is characterized by defective insulin signaling with 




As mentioned before, BVR-A is characterized by the ability to carry out a Ser/ 
Thr/Tyr kinase activity through which BVR-A regulates cell signaling and gene 
expressions (reviewed in [97]). BVR-A kinase activity requires the 
phosphorylation of Tyr198/228/291 promoted by IR [214]. Therefore BVR-A is a 
direct target of IR kinase activity and once IR-phosphorylated is able to 
phosphorylates IRS1 on Ser inhibitory domains, thus representing an upstream 
regulator in the insulin signaling cascade [214] (Fig. 14). In addition, BVR-A 
contains specific motifs in its sequence through which modulates IR kinase activity 
both negatively and positively [215] (Fig. 14). Based on the involvement of BVR-
A in the insulin signaling we hypothesize that an impairment of the kinase activity 
of BVR-A could be associated with the onset of BIR in AD.  
 
Fig. 14. Proposed mechanism leading to BIR in AD. BVR-A once IR-phosphorylated is able to 
phosphorylates IRS1 on Ser inhibitory domains. In addition, BVR-A modulates IR kinase activity both 
negatively and positively.  
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2 AIMS OF THIS WORK 
Within this scenario, we focused our attention on the impairment of molecular 
pathways, including autophagy, insulin signaling and inflammation, that might be 
involved in neurodegenerative process responsible to the development of 
Alzheimer-like dementia in DS subjects. We propose that the alteration of these 
processes is joined by a “leitmotif” -OS- as cause and/or consequence of increased 
free radical burden. One of the main goals of this research is to clarify the intricate 
relationship between increased OS and alteration of mTOR/autophagy signaling. 
To this aim, we analyzed the mTOR axis in DS mouse model (Ts65Dn) at different 
ages and evaluated the effects of autophagy inhibition (by rapamycin) on protein 
oxidative damage in neuroblastoma cell line (SH-SY5Y) (Project 1).  
Increasing evidence supports the involvement of inflammation-related miRNAs in 
neural development and neural function under pathological conditions [229-231]. 
We hypothesize that an inflammation-mediated dysregulation of both miR146a 
and miR155 could contribute to development of neurobehavioral abnormalities as 
well as contribute to age-related inflammatory neurodegenerative disorders 
including AD (project 2). To this purpose, we investigated the expression and cell-
specific distribution of both miR146a and miR155 in the developing hippocampus 
from controls, DS subjects with and without AD pathology. In addition, we 
evaluated the levels of these miRNAs, their putative targets as well as the levels of 
IL-1β in human hippocampus from sporadic AD (sAD) at different stages of the 
disease and in experimental models of DS (Ts65Dn) and AD (APP/PS1mice). 
Based on the discovery that AD brain is characterized by BIR and because we 
previously demonstrated that OS induced impairment of BVR-A, an upstream 
inhibitory regulator in the insulin signaling, we hypothesize the involvement of 
OS-induced BVR-A dysregulation in the onset of BIR in AD (Project 3). To this 
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purpose, we evaluated the age dependent changes of (i) BVR-A levels and 
activation, (ii) total amount of OS markers (PC, HNE, 3-NT) as well as (iii) 
IR/IRS1 levels and activation in AD mouse model (3xTg-AD). Furthermore, ad 
hoc in-vitro experiments have been performed to clarify the contribution of 
ROS/RNS on insulin resistance and considering that mTOR is able to 
phosphorylate IRS1 we investigated whether the insulin resistance is associated 
with mTOR hyperactivation.
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3 MATERIALS AND METHODS 
3.1 Cell Culture and Treatment  
The SH-SY5Y neuroblastoma cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, penicillin (20 U/ml) and streptomycin (20 mg/ml; GIBCO, 
Gaithersburg, Md., USA). Cells were maintained at 37°C in a saturated humidity 
atmosphere containing 95% air and 5% CO2.  
 
Rapamycin Treatment SH-SY5Y were seeded at a 40 × 103/ cm2 density in 6-well 
culture dishes. After 24 h incubation, the medium was replaced with DMEM with 
1% FBS for the starved group (St) and DMEM with 1% FBS and rapamycin (Pfizer 
Italia, Latina, Italy) 1μM for the rapamycin-treated (Rp) group. Rapamycin 
treatment was repeated daily to maintain the inhibition of mTOR, and cells were 
harvested at 24, 48 and 72h after the first treatment. Experimental analyses were 
performed on SH-SY5Y cells prior to rapamycin treatment to assess the subchronic 
increase in OS cells cultured with 1% FBS, as also reported by literature data [216, 
217] and to assess the therapeutic concentration of rapamycin (data not shown). 
 
Insulin Treatment SH-SY5Y were seeded at a 40 × 103/ cm2 density in 6-well 
culture dishes. To test the responsiveness of our cellular model to insulin signaling 
the cells were pre-treated with insulin (Humulin, Ely-Lilly, Inadianapolis, IN, 
USA) 0.1 µM or vehicle (PBS) for 24 h. Insulin concentration has been selected 
based on previous reports [218, 219]. Then, medium was discarded, cells were 
washed twice with PBS, and rechallenged with DMEM with 1% FBS containing 
insulin (0.1–0.5–1–5 µM) or vehicle (PBS) for an additional hour to mimic insulin 
over-exposure. 
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Peroxynitrite/Hydrogen peroxide Treatment SH-SY5Y were seeded at a 40 × 103/ 
cm2 density in 6-well culture dishes. After 24 h incubation, the medium was 
replaced with DMEM with 1% FBS and the cells were treated with peroxynitrite 
(ONOO, 50–500 µM) or hydrogen peroxide (H2O2, 1–50 µM) (Sigma-Aldrich, St 
Louis, MO, USA, #16911) or vehicle (PBS) for 24 h.  
 
BVR-A Silencing To test the effects of BVR-A silencing on the insulin signaling, 
SH-SY5Y were seeded at a 40 × 103/ cm2 density in 6-well culture dishes. After 
24 h incubation, medium was replaced with DMEM with 1% FBS without 
antibiotics and the cells were treated in parallel with insulin (0.1 µM), transfected 
with 25pmol of BVR-A small-interfering RNA (siRNA) (Ambion, Life 
Technologies, LuBioScience GmbH, Lucerne, Switzerland, #4392420) using 
Lipofectamine RNAiMAX reagent (Invitrogen, Life Technologies, LuBioScience 
GmbH, Lucerne, Switzerland, #13778-030) according to the manufacturer's 
protocol, or co-treated with insulin (0.1 µM) and BVR-A siRNA for 24 h. At the 
end of each treatment, cells were washed twice with ice could PBS, collected by 
mechanical scraping and the proteins were extracted as described below. 
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3.2 Animals 
Mice were housed in clear Plexiglas cages (20 × 22 × 20 cm) under standard 
laboratory conditions at a temperature of 22 ± 2°C, 70% humidity, 12 h light/dark 
cycle and free access to food and water. All the experiments were performed in 
strict compliance with animal welfare National Laws (DL 116/92) and European 
Communities Council Directives (86/609/EEC). All efforts were made to 
minimize the number of animals used in the study and their suffering. Animals 
were sacrificed at the selected age and brain area sectioned and store at  
-80°C until use. 
 
Ts65Dn mice were generated by repeatedly backcrossing Ts65Dn trisomic 
females with (C57BL/6JxC3H/HeJ) F1 hybrid males; the parental generations 
were purchased from The Jackson Laboratories Inc. These breeding pairs produce 
litters containing both trisomic (Ts65Dn) and disomic (2N) offspring. The animals 
employed in this study were produced by two generations of backcrossing. Pups 
were genotyped to determine the trisomy using standard PCR, as described by 
Reinholdt et al. [220]. In addition, in all animals the recessive retinal degeneration 
1 mutation (Pdebrd1), which results in blindness in homozygotes, was detected by 
using a standard PCR [221]. Mice were sacrificed at 4-5 weeks and at 6, 12 and 18 
months of age, hippocampus and frontal cortex ware extracted (Ts65Dn mice, n= 
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3xTg-AD mice represent a mouse model of Alzheimer’s disease that express 3 
mutant human genes (APPSwe, PS1M146V, and tauP301L) and have been 
genetically engineered by La Ferla and colleagues at the Department of 
Neurobiology and Behavior, University of California, Irvine [222]. Colonies of 
homozygous 3xTg-AD and WT mice were established at the vivarium of the 
Experimental Zooprophylactic Institute of Puglia and Basilicata (Foggia, Italy).  
The 3xTg-AD mice background strain is C57BL6/129SvJ hybrid and genotypes 
were confirmed by PCR on tail biopsies [222]. 3, 6, 12 and 18 months-old 3xTg-
AD male mice (n=6 per group) and their wild-type (WT) male littermates (n=6 per 
group) were sacrificed and the hippocampus was extracted, flash-frozen, and 
stored at -80°C until further use. 
 
APP/PS1 mice are a double transgenic mouse model of AD, which express a 
chimeric mouse/human amyloid precursor protein (APP, Mo/HuAPP695swe: APP 
Swedish mutation) and a mutant human Presenilin 1 (PS1-dE9), leading to an 
increased in the amount and an accelerated deposition rate of Aβ throughout the 
brain and memory impairment earlier than single APP transgenic littermates. 
Hippocampi from wild type (WT) and APP-PS1 male mice were collected at 3, 
11-13 and 19-21 months of age (n=5). Brain tissue was fresh-frozen in liquid 
nitrogen and stored at -80°C until used for RNA isolation. 
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3.3 Human material 
The subjects included in this study were selected from the databases of the 
Departments of Neuropathology of the Academic Medical Center, University of 
Amsterdam, The Netherlands, from the Institute of Neurology, Medical University 
of Vienna, Austria (in the frame of a project approved by the Ethical Committee 
of the Medical University of Vienna, entitled “Molecular neuropathologic 
examinations of neurodegeneration-related proteins in Down-syndrome, Ek Nr. 
1316/2012), from the Netherlands Brain Bank (NBB) and from the Institut de 
Neuropatologia, Servicio Anatomia Patologica, Hospital Bellvitge, Barcelona, 
Spain. Informed consent was obtained for the use of brain tissue and for access to 
medical records for research purposes. Tissue was obtained and used in a manner 
compliant with the Declaration of Helsinki and the Academic Medical Center 
(AMC) Research Code provided by the Medical Ethics Committee of the AMC 
(Amsterdam, The Netherlands). The local ethical committees of the participating 
centers gave permission to undertake the study. We included brains of fetuses at 
different gestational weeks (9-41 GW), neonates and children from control and DS 
patients (Table 1). Fetal brains were preserved after spontaneous or induced 
abortions with appropriate maternal written consent for brain autopsy. We 
performed a careful histological and immunohistochemical analysis and evaluation 
of clinical data (including genetic data, when available). We only included, as 
control cases, specimens displaying a normal hippocampal and cortical structure 
for the corresponding age and without any significant brain pathology. 
Furthermore (Table 1), we obtained adult brain tissue at autopsy from adult 
controls (without evidence of degenerative changes, and lacking a clinical history 
of cognitive impairment), DS patients with AD and sAD cases at different stages 
of the disease; pathology was staged according to criteria recommended for 
neurofibrillary degeneration [223]. We acknowledge that in studies using 
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postmortem fetal tissue the availability of brain tissue represent a major limitation, 
because the number of cases with permission for brain autopsy at early 
developmental stages is limited and frozen representative material (i.e. 
hippocampus) is often not available. 
 
Table 1. Cases included in this study (hippocampus) 
Group Age range n Sex (m/f) 
Controls 
13-23 gw 10 5/5 
24-32 gw 12 7/5 
33-41 gw 8 4/4 
1-15 d 6 3/3 
2 -8 m 8 4/4 
1-15 yrs 5 2/3 
25-86 yrs 30 15/15 
Down 
Syndrome 
14-23 gw 10 5/5 
24-32 gw 5 2/3 
33-41 gw 5 2/3 
1-15 d 5 3/2 
2 -8 m 5 3/2 
1-15 yrs 5 2/3 
50-64 yrs 






26: 9 stage II; 8 




gw: weeks of gestation; d/wk/yrs: postnatal days/weeks years; m = male; 
 f = female; neurofibrillary tangle, NFT stage: II-VI. 
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3.4 Sample Preparation and Western blot analysis  
Total protein extracts were prepared in RIPA buffer (pH 7.4) containing Tris-HCl 
(50 mM, pH 7.4), NaCl (150 mM), 1% NP-40, 0.25% sodium deoxycholate, EDTA 
(1 mM), 0.1% sodium dodecyl sulfate (SDS), supplemented with proteases 
inhibitors [phenylmethylsulfonyl fluoride (PMSF, 1 mM), sodium fluoride (NaF, 
1 mM) and sodium orthovanadate (Na3VO4, 1 mM)]. Hippocampus, frontal cortex 
and the cellular pellets of different treatment were homogenized by 20 passes with 
a Wheaton tissue homogenizer and centrifuged for 1h at 16,000 g, 4°C to remove 
cellular debris. The supernatant was then extracted to determine the total protein 
concentration by the bicinchoninic acid assay (Pierce, Rockford, IL., USA). For 
Western blots, 30μg of were resolved on 12% and 7.5% SDS–PAGE using 
Criterion Gel TGX and blotted onto a nitrocellulose membrane (Bio-Rad, 
Hercules, Calif., USA). Before the transfer process, the image of the total protein 
load was acquired to perform normalization of blot data analysis. The membranes 
were blocked with 3% bovine serum albumin in 0.5% Tween-20/Trisbuffered 
saline (TTBS) and incubated overnight at 4°C with primary antibodies: anti-BVR-
A (1:5000, abcam, Cambridge, United Kingdom, #ab90491), anti-BVR-A (1:1000, 
Sigma-Aldrich, St Louis, MO, USA, #B8437), anti-IRβ (1:1000, Cell Signaling, 
Bioconcept, Allschwill, Switzerland, #3020), anti-phospho(Tyr1162/ 1163)-IRβ 
(1:500, Santa Cruz, Santa Cruz, CA, USA, #sc-25103), anti-IRS1 (1:1000, Cell 
Signaling, Bioconcept, Allschwill, Switzerland, #3407), anti-phospho(Ser307)-
IRS1 (1:500, Cell Signalling, Bioconcept, Allschwill, Switzerland, #2381), anti-
phospho (Tyr632)-IRS1 (1:500, Santa Cruz, Santa Cruz, CA, USA, #sc-17196), 
anti-mTOR (1:1000, Cell Signaling, Bioconcept, Allschwill, Switzerland, #2983), 
anti-phospho(Ser2448)-mTOR (1:500, Cell Signaling, Bioconcept, Allschwill, 
Switzerland, #5536), anti-HO1 (1:1000, Enzo Life Sciences, Farmingdale, NY, 
USA, #ADI-SPA-895), anti-TNF-α (1:1000, EMD Millipore, Billerica, MA, USA, 
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#AB1837P), anti-phospho-Tyrosine (1:2000, Cell Signaling, Bioconcept, 
Allschwill, Switzerland, #9416), anti-3NT (1:500, Santa Cruz, Santa Cruz, CA, 
USA, #sc-32757) and anti-LC3 (Novus Biologicals, Littleton, Colo., USA). After 
3 washes with TTBS the membranes were incubated for 60 min at room 
temperature with anti-rabbit/mouse/goat IgG secondary antibody conjugated with 
horseradish peroxidase (1:5000; Sigma-Aldrich, St Louis, MO, USA). Membranes 
were developed with the Super Signal West Pico chemiluminescent substrate 
(Thermo Scientific, Waltham, MA, USA), acquired with Chemi-Doc MP (Bio-
Rad, Hercules, CA, USA) and analyzed using Image Lab software (Bio-Rad, 
Hercules, CA, USA) that permits the normalization of a specific protein signal with 
the β-actin signal in the same lane or total proteins load. 
3.5 Slot Blot 
For total Protein Carbonyls (PC) levels: total protein extract samples (5µl), 12% 
SDS, and 20 mM 2,4- dinitrophenylhydrazine (DNPH) were incubated at room 
temperature for 20 min, followed by neutralization with neutralization solution (2 
M Tris in 30% glycerol) and then loaded onto nitrocellulose membrane as 
described below.  
For total (i) protein-bound 4-hydroxy-2-nonenals (HNE) and (ii) 3-nitrotyrosine 
(3-NT) levels: total protein extract samples (10µl), 10μl of Laemmli buffer 
containing 0.125 M Tris base, pH 6.8, 4% (v/v) SDS and 20% (v/v) glycerol were 
incubated for 20 min at room temperature and then loaded onto nitrocellulose 
membrane as described below. 
The resulting samples (250 ng) were loaded in each well onto a nitrocellulose 
membrane with a slot blot apparatus under vacuum pressure. The membrane was 
blocked for 2h with a solution of 3% (w/v) bovine serum albumin in TBS 
containing 0.2% (v/v) Tween 20 and incubated with anti-2,4-
dinitrophenylhydrazone (DNP) adducts polyclonal antibody (1:100, EMD 
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Millipore, Billerica, MA, USA, #MAB2223) or HNE polyclonal antibody (1:2000, 
Novus Biologicals, Abingdon, United Kingdom, #NB100-63093) or anti-3-NT 
polyclonal antibody (1:1000, Santa Cruz, Santa Cruz, CA, USA, #sc-32757), 
respectively, for 2 h at room temperature. Membranes were washed and incubated 
with anti-rabbit IgG alkaline phosphatase secondary antibody (1:5000, Sigma-
Aldrich) for 1 h at room temperature. After 3 washes the membrane was developed 
with Sigma fast tablets (5-bromo-4-chloro-3-indolyl phosphate/nitroblue 
tetrazolium substrate [BCIP/NBT substrate]). Blots were dried, acquired with 
Chemi-Doc MP (Bio-Rad, Hercules, CA, USA) and analyzed using Image Lab 
software (Bio-Rad, Hercules, CA, USA). No non-specific binding of antibody to 
the membrane was observed. 
3.6 Immunoprecipitation  
The immunoprecipitation procedure was performed as previously described [224], 
with minor modifications. Briefly, 150 µg of proteins were dissolved in 500 µl of 
RIPA buffer (10 mM Tris, pH 7.6; 140 mM NaCl; 0.5% NP-40) supplemented 
with proteases inhibitors and incubated with 1 µg anti-BVR-A polyclonal antibody 
at 4°C overnight. Immunocomplexes were collected using protein A/G suspension 
for 2h at 4°C and washed 5 times with immunoprecipitation buffer. 
Immunoprecipitated BVR-A was recovered by re-suspending the pellets in 
reducing SDS buffers and electrophoresing them on 12% gels, followed by western 
blot analysis. Total BVR-A was used as a loading control as previously described 
[215, 219, 225, 226]. 
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3.7 2′,7′-Dichlorofluorescein Assay 
ROS levels were detected by the 2′,7′-dichlorofluorescein method [227] with 
minor modifications. Briefly, cells were challenged with 10 mM 2′,7′-
dichlorofluorescein diacetate for 30 min in the incubator, then washed twice with 
PBS and finally gently scraped into 1 ml of PBS. The cellular suspension was then 
transferred into a fluorescence cuvette where the ROS-driven conversion to the 
highly fluorescent 2′,7′-dichlorofluorescein was monitored by fluorescence 
intensity measured by an FP 6300 Jasco spectrofluorometer with excitation 
wavelength at 502 nm (bandwidth 5 nm) and emission wavelength at 520 nm 
(bandwidth 5 nm). 
3.8 BVR-A reductase activity 
We determined BVR-A activity in hippocampal tissues extracted from both 3xTg-
AD and WT mice using a BVR assay kit (Sigma-Aldrich, St Louis, MO, USA 
#CS1100) as per manufacturer’s instructions with minor modification. Briefly, 150 
µg of proteins were prepared for the assay and loaded in the 96 well plates. BVR 
positive control solution (2.5, 5, 10, 15 and 20 µL) was included in the assay for 
generation of a standard curve. 50 µL assay buffer and 150 µL working solution 
(containing NAPDH, substrate solution and assay buffer) were added to each 
standard and sample on the plate. The plate was placed on the UV–vis plate reader 
at 37°C and read every minute for 10 min. The reading at 5 min had a linear 
reaction rate, and was chosen for BVR activity calculations. Values are expressed 
as Unit (U)/ml [Unit definition as per manufacturer’s instruction: 1 unit of BVR 
will transform 1 nanomole of biliverdin to bilirubin in an NADPH dependent 
reaction at pH 8.5 at 37°C]. 
  
MATERILAS AND METHODS 
51 
3.9 Tissue preparation and In situ hybridization 
Paraffin-embedded tissue was sectioned at 5 μm, mounted on pre-coated glass 
slides (Star Frost, Waldemar Knittel GmbH, Brunschweig, Germany), and used for 
in situ hybridizations and immunocytochemistry. Sections of all specimens were 
processed for hematoxylin and eosin (HE), as well as for immunocytochemical 
stainings for a number of neuronal and glial markers.  
In situ hybridization (ISH) for miR146a and miR155 were performed on 5 μm 
thick FFPE tissue using 5′ - fluorescein (FAM) or 5′-3′ double digoxygenin (DIG)-
labeled Superior probes as described previously [228]. The probe sequences used 
were: miR146a-5p: 5’ FAM-AacCcaTggAauTcaGuuCucA; miR155-5p: 5’ DIG-
AccCcuAucAcgAuuAgcAuuaA -DIG (capital = LNA modification, small = 2-o-
methyl modification) all from Ribotask ApS (Odense, Denmark). Briefly, after the 
sections were deparaffinized and heat treated to undo protein crosslinks (10 min at 
120°C in a pressure cooker), the probes were hybridized at 56°C for 1h. The 
hybridization was detected with an alkaline phosphatase (AP)-labeled anti-DIG or 
anti-FAM antibody (Roche Applied Science, Basel, Switzerland). NBT/BCIP was 
used as chromogenic substrate for AP. Negative controls sections were with a 
scrambled probe or without any probe in the hybridization step and without 
primary antibody. Aβ (Mouse clone 6F/3D; DAKO; 1:200), was used in the routine 
immunocytochemical analysis of DS-AD and sAD cases. Single-label 
immunocytochemistry was developed using the Powervision kit (Immunologic, 
Duiven, The Netherlands). 3,3-Diaminobenzidine (Sigma, St. Louis, USA) was 
used as the chromogen. Sections were counterstained with hematoxylin. For the 
double-staining, combining immunohistochemistry with ISH, the sections were 
first processed for ISH and then processed for immunohistochemistry with glial 
fibrillary acidic protein (GFAP; monoclonal mouse, Sigma, St. Louis, Mo, USA; 
1:4000), GFAPδ. polyclonal rabbit, Kindly provided by Dr. E.M. Hol [39]; 1:500), 
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Vimentin (mouse clone V9 DAKO, Glostrup, Denmark 1:1000) and HLA-
DP/DQ/DR (HLA-DR, mouse clone CR3/43; Dako; 1:100) antibodies. Signal was 
detected using the chromogen 3-amino-9 ethylcarbazole (Sigma-Aldrich, St. 
Louis, MO, USA). 
3.10 Evaluation of In situ hybridization 
The intensity of labeling was evaluated, as previously described [229, 230], using 
a semi-quantitative scale ranging from 0 to 3 (0: negative; 1: weak; 2: moderate; 
3: strong staining). The score represents the predominant cell staining intensity 
found for each case. The frequency of positive glial cells was also evaluated using 
a semi-quantitative scale ranging from 1 to 3, including score 1 (rare labeling 
observed in <10% of cells), 2 (sparse, labeling observed in 11 to 50% of cells), and 
3 (high, labeling observed in >50% of cells) to assess the relative number of 
positive glial cells within the hippocampus. As proposed before [229-231], the 
product of these two values (intensity and frequency scores) was taken to give the 
overall score (total labeling score).  
3.11 RNA isolation 
For RNA isolation, frozen tissue material was homogenized in Qiazol Lysis 
Reagent (Qiagen Benelux, Venlo, The Netherlands). The total RNA including the 
miRNA fraction was isolated using the miRNeasy Mini kit (Qiagen Benelux, 
Venlo, the Netherlands) according to manufacturer’s instructions. The 
concentration and purity of RNA were determined at 260/280 nm using a 
Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 
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3.12 Real-time quantitative analysis (qPCR) 
miRNA (miR146a, miR155 and the reference small nuclear RNAs, Rnu6B and 
Rnu44) expression was analyzed using Taqman microRNA assays (Applied 
Biosystems, Foster City, CA). cDNA was generated using Taqman MicroRNA 
reverse transcription kit (Applied Biosystems, Foster City, CA) according to 
manufacturer’s instructions and the PCRs were run on a Roche Lightcycler 480 
thermocycler (Roche Applied Science, Basel, Switzerland). Quantification of 
data was performed using the computer program LinRegPCR in which linear 
regression on the Log (fluorescence) per cycle number data is applied to 
determine the amplification efficiency per sample [232, 233]. The starting 
concentration of each specific product was divided by the starting concentration 
of reference genes (geometric mean of Rnu6B and Rnu44 values) and this ratio 
was compared between groups. To evaluate IL-1β and the miRNA targets 
(IRAK1, IRAK2, CFH, TRAF6, SHIP1), 2.5µg of total RNA was reverse-
transcribed into cDNA using oligo dT primers. PCR primers (Eurogentec, 
Belgium) were designed using the Universal ProbeLibrary of Roche 
(https://www.roche-applied-science.com) on the basis of the reported cDNA 
sequences. We used the following primers: IL-1β (mouse, forward: 
tgaagttgacggaccccaaa; reverse: tgatgtgctgctgcgagatt; human, forward: 
gcatccagctacgaatctcc; reverse: gaaccagcatcttcctcagc), IRAK1 (mouse, forward: 
ggatcagctccaccttcaga; reverse: cccagaagaatgtccagtcg; human, forward: 
gcccgaggagtacatcaaga; reverse: ctctgaccagccaaggtctc), IRAK2 (mouse, forward: 
tctgccggaacacttcatca; reverse: ggtaaggacctcggccaata; human, forward: 
cctcctctgaggcctgtgt; reverse: tgatctcaatttgccacgaa), TRAF6 (mouse, forward: 
ttgcacattcagtgtttttgg; reverse: tgcaagtgtcgtgccaag; human, forward: 
tggcattacgagaagcagtg; reverse: tggacatttgtgacctgcat), CFH (mouse, forward: 
gaaaaaccaaagtgccgaga; reverse: ggaggtgatgtctccattgtc; human, forward: 
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cctgacctcccaatatgtaaaga; reverse: ttccttaacattcccattgagg), EF1A (human, 
forward: atccacctttgggtcgcttt; reverse: ccgcaactgtctgtctcatatcac), Small Nuclear 
Ribonucleoprotein D3 polypeptide 18kDa (SNRPD3, human, forward: 
atacagagatggccgagtgg; reverse: taacatgggtgcgttcttca), TATA box-binding protein 
(Tbp, mouse; foward: ggagaatcatggaccagaaca; reverse: gatgggaattccaggagtca) 
and hypoxanthine phosphoribosyl transferase (Hprt; mouse, forward: 
tcctcctcagaccgctttt; reverse: cctggttcatcatcgctaatc). For each PCR, a mastermix 
was prepared on ice, containing per sample: 1 µl cDNA, 2.5 µl of 2x 
SensiFASTTM SYBR Green Reaction Mix (Bioline Inc, Taunton, MA, USA), 0.4 
µM of both reverse and forward primers and the PCRs were run on a Roche 
Lightcycler 480 thermocycler (Roche Applied Science, Basel, Switzerland). 
Quantification of data was performed as described for the Taqman PCR and the 
starting concentration of each specific product was divided by the geometric 
mean of the starting concentration of reference genes (Tbp and Hprt for mouse; 
EF1A and SNRPD3 for human) and this ratio was compared between 
patient/control groups. 
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3.13 Immunohistochemistry 
Briefly both 3xTg and WT mice at 3, 6, 12 and 18 months of age (n=3 per group, 
per genotype) were intra-cardioventricularly perfused with saline followed by 
fixation solution (4% paraformaldehyde in PBS 0.1 M, pH 7.4) at a flow rate of 36 
ml min-1 [234]. Brains were post-fixed in the fixation solution for 1 day and then 
transferred in 0.02% sodium azide in PBS. Free-floating coronal sections of 50 μm 
thickness were obtained using a vibratome slicing system (microM, Walldorf, 
Germany) and stored at 4°C in 0.02% sodium azide in PBS. The endogenous 
peroxidase activity was quenched for 30 min in 0.3% H2O2. Sections were then 
pretreated in 90% formic acid and incubated overnight at 4°C either with the 
monoclonal 6E10 antibody (1:3000, Signet Laboratorie– Covance, Emeryville, 
CA, USA, #sig-39320) for Aβ staining, or with the human-specific anti-tau 
antibody, HT7 (1:2000, Thermo Scientific Pierce Product, Rockford, IL, USA, 
#MN1000). After removing the primary antibody in excess, sections were 
incubated with the appropriate secondary antibody and developed with 
diaminobenzidine substrate using the avidin-biotin horseradish peroxidase system 
(Vector Laboratories, Inc, Burlingame, CA, USA, #SK-4100; #PK-6100). All 
stained slices were viewed using a Nikon 80i Eclipse microscope equipped with a 
DS-U1 digital camera, and NIS-elements BR software (Nikon, Tokyo, Japan). The 
intensity of Aβ and tau immunostaining was measured semi-quantitatively as 
regional optical density using the Scion Image software, as previously reported 
[234-236]. Per each animal, measurements were obtained in at least 3 consecutive 
sections containing the region of interest. The averaged optical densities of non-
immunoreactive regions of each section were used for background normalization. 
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3.14 Statistical Analysis 
Statistical analysis was performed using Graphpad Prism® 5.0 software 
(Graphpad software Inc., La Jolla, CA, USA). 
In the first project all data are expressed as means ± SD per group. All statistical 
analyses were performed using a nonparametric one-way ANOVA with post hoc 
Bonferroni t tests. p < 0.05 was considered significant. 
In the second project the two-way ANOVA followed by the Bonferonni’s post hoc 
test was used to analyze the effect of the Ts65Dn trisomy or the APP-PS1 mutation 
and age on the expression of miRNAs and their targets in Ts65Dn or APP-PS1 
mice. To compare Alzheimer’s patient samples of different Braak stages, a non-
parametric Kruskal–Wallis test was used, followed by the Mann-Whitney U test 
to assess differences between individual groups. Correlations between miRNAs 
and their targets was assessed using the Spearman’s rank test. A P value of < 0.05 
was considered significant. 
In the third project all data are presented as means ± SEM of n independent samples 
per group. Student’s t test or a nonparametric one-way ANOVA with post hoc 
Turkey’s t –tests were applied for statistical analysis. P ˂ 0.05 was considered 
significantly different from the reference value. 
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4 RESULTS  
4.1 Project 1: Increased mTOR Signaling Contributes to the Accumulation 
of Protein Oxidative Damage in Ts65Dn Mice 
As previously described, an impairment in mTOR signaling causes the alteration 
of the autophagy-lysosome pathway (the major cellular pathway for the removal 
of Aβ and tau aggregates) resulting in abnormal protein aggregates, which 
characterizes both AD and DS pathology. Recent studies from our laboratory 
reported, in human DS samples, an early accumulation of protein oxidative damage 
concomitant with the alteration of mTOR/ autophagy signaling. However, the 
relationship between OS and mTOR/autophagy signaling is intricate and needs to 
be clariﬁed. To this purpose, we analyzed the protein oxidation levels and the 
integrity of the mTOR axis in Ts65Dn mice at different ages compared with age-
matched euploid mice as well as the effects of autophagy inhibition by blocking 
mTOR on protein oxidative damage in the SH-SY5Y cell line. 
4.1.1 mTOR/autophagy axis and protein oxidation in Ts65Dn Mice  
We evaluated, by Western Blot, the levels of mTOR and the levels of mTOR 
phosphorylated on Ser 2448 (which reflects the activation of the mTOR) in the 
hippocampus of Ts65Dn mice at 6 and 12 months of age. An increase of both 
expression and phosphorylation of mTOR was observed in Ts65Dn mice at 6 
months of age compared with age-matched euploid controls (about 1.3-fold, 
p<0.05, and 1.4-fold, p<0.05, respectively; Fig. 14). In contrast, at 12 months 
mTOR did not show signiﬁcant differences in the expression levels, between the 
two groups of comparison, but demonstrated alterations in the phosphorylation 
levels (about 1.35-fold, p < 0.05; Fig. 14). Based on the fact that mTOR controls 
in a negative manner the autophagy activity by inhibiting the autophagosome 
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formation, we evaluated by Western Blot the LC3 II/I ratio, which it is used as 
marker of autophagosome formation. Our data demonstrate that increased mTOR 
phosphorylation is associated with a signiﬁcant decrease in the LC3 II/I ratio in 
Ts65Dn mice at both ages compared with euploid mice (about 0.8-fold, p < 0.05; 
Fig. 14). The evaluation of protein oxidation by slot blot showed an increase in 
protein nitration and protein-bound 4-hydroxynonenal but not of protein carbonyls 
in 12 months-old Ts65Dn mice compared with age-matched euploid mice (about 
1.5-fold, p < 0.05; Fig. 14). These results indicate that, despite the early aberrant 
hyperphosphorylation of mTOR coupled with the reduction of autophagosome 
formation, protein oxidative damage become signiﬁcant only in adult animals 
suggesting that the accumulation of oxidative damage become consistent only after 




Fig. 14. mTOR signaling and protein oxidation in the Ts65Dn mouse hippocampus after 6 (6M) and 12 
months (12M). (A) representative Western blot image with protein bands for mTOR expression levels, mTOR 
phosphorylation (Ser 2448) levels and LC3 (I and II) levels of samples from euploid (Eu) and Ts65Dn (Ts) 
mouse hippocampi at 6 and 12 months of age is shown. The analysis of experimental data is reported by 
histograms for mTOR expression (B), phosphorylated mTOR (pmTOR)/level ratio (C) and LC3 II/I ratio (D). 
(E) Data of total protein oxidation (protein-bound HNE and protein-bound 3-NT) obtained by slot blot analysis 
of euploid and Ts65Dn samples. Densitometric values shown in all the histograms are the mean of 8 individual 
samples per group normalized per total protein load and are displayed as percentage of euploid 6-month 
samples, set as 100%; * p < 0.05.  
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4.1.1 Effects of Rapamycin Treatment on Protein Oxidation in SH-SY5Y 
Cells  
To conﬁrm the involvement of the mTOR in the accumulation of the oxidative 
damage we evaluated the levels of protein oxidative modifications with inhibited 
mTOR in SH-SY5Y cell line treated with rapamycin for 24, 48 and 72h. The cells 
were cultured in DMEM with 10% FBS in control group, in DMEM with 1% FBS 
in the starved group (St) and in in DMEM with 1% FBS and 1μM of rapamycin 
added daily in rapamycin-treated group (Rp). Data on cell viability by MTT assay 
demonstrated no signiﬁcant alterations in St and Rp group compared to controls 
(data not shown). The Western Blot data showed that rapamycin administration 
decreased mTOR expression when compared with control and St group after 24, 
48 and 72h (about 0.6-, 0.55- and 0.5-fold, p < 0.05; Fig. 15). However only after 
a 72h treatment the levels of mTOR phosphorylated on Ser 2448 were reduced in 
the Rp group compared to St group. Nonetheless the autophagosome formation, as 
indexed by the LC3 II/I ratio, was increased in Rp group compared to St group 
already after 48h (about 1.7-fold, p < 0.05; Fig. 15) and 72h (about 1.3-fold, p < 
0.05; Fig. 15) that was consistently with the decreased expression and 
phosphorylation of mTOR in Rp group at 24, 48 and 72h. Finally, a signiﬁcant 
decrease of protein-bound 3-NT and protein-bound HNE levels were showed 
respectively at 48 h (about 0.8-fold, p < 0.05; Fig. 15) and 72 h (about 0.7-fold, p 
< 0.05; Fig. 15) and only at 72 h (about 0.8-fold, p < 0.05; Fig. 15) in Rp group 
compared to St group. Protein oxidation data were further confirmed by the 
analysis of total ROS production from the 2′,7′-dichlorofluorescein assay. Overall, 
our results prove that the rapamycin treatment, by inhibiting mTOR and enhancing 
the autophagosome formation, is able to reduce protein oxidative damage, thus 





Fig. 15. mTOR signaling and protein oxidation in SH-SY5Y cells treated with rapamycin. (A) 
representative Western blot image with protein bands for mTOR expression levels, mTOR phosphorylation 
(Ser 2448 ) levels and LC3 (I and II) levels of SH-SY5Y samples from control cells (C), starved cells (S) and 
rapamycin-treated (R) groups is shown. The analysis of experimental data is reported by histograms for mTOR 
expression (B), phosphorylated mTOR (p-mTOR)/level ratio (C) and LC3 II/I ratio (D). (E) Data of total ROS 
production from the 2′,7′-dichlorofluorescein assay. (F) Data of total protein oxidation (protein-bound HNE 
and protein-bound 3-NT) obtained by slot blot analysis of cells treated or not with rapamycin. Densitometric 
values shown in all the histograms are the mean of 3 individual samples per group normalized per total protein 




4.2 Project 2: Developmental expression and dysregulation of miR146a and 
miR155 in Down's syndrome and and Alzheimer's disease  
As previously described, miRNAs are key post-transcriptional regulators of gene 
expression. Increasing evidence support their involvement in neural development 
and function under physiological and pathological conditions [237-239]. 
Therefore, their dysregulation can contribute to the development of 
neurobehavioral and neurodegenerative abnormalities. 
miR146a and miR155 are two NF-κB-inducible miRNAs, associated with the 
activation of the IL-1β pathway and able to modulate astrocyte-mediated 
inflammation in culture. However little is known about their expression pattern in 
both development and aging of human brain. We hypothesized that the 
inflammation-mediated dysregulation of both miR146a and miR155 in fetal brain 
(i.e. in DS) could contribute to the development of neurobehavioral abnormalities, 
as well as, to age-related inflammatory neurodegenerative disorders including AD 
pathology. In order to clarify the potential link between deregulation of 
inflammation-related miRNAs, neurobehavioral deficits and AD-pathology; we 
investigated the expression and cell-specific distribution of both miR146a and 
miR155 in the developing hippocampus of healthy subjects, of patients with DS 
and in patients with DS-AD pathology. In addition, we evaluated the levels of these 
miRNAs, their putative targets as well as the levels of IL-1β in human 
hippocampus from sAD, at different stages of the disease, and in experimental 




4.2.1 miR146a and miR155 expression in the developing control 
hippocampus  
By in situ hybridization, the hippocampal expression of miR146a and miR155 was 
investigated at different prenatal (from 13 to 41 GW) and postnatal ages (from day 
1 to 8 months and 1-15 yrs; Table 1). The analysis showed that both miR146a (Fig. 
16) and miR155 (Fig. 17) are detectable in the hippocampus in the second trimester 
of gestation. At GW 22 both miRNAs are expressed in neurons of the stratum 
pyramidale (CA1-CA3) and dentate gyrus (DG). Their expression persisted at later 
prenatal and postnatal age. In the second trimester of gestation, miR146a was also 
detected in the ventricular/subventicular zone (VZ/SVZ; Fig. 16) and co-localized 
with neuronal precursor markers (vimentin and GFAPδ). In adult control 
hippocampus both miRNAs are mainly detected in neuronal cells of the stratum 
pyramidale and in DG, whereas expression in astroglial cells within the 
hippocampal region was low or under detection level (Fig. 19A, Fig. 20A and Fig. 
21 A-B). 
4.2.1 miR146a and miR155 expression in the developing Down's syndrome 
hippocampus  
In DS hippocampus, the expression pattern of miR146a and miR155 was similar 
to that observed in age-matched controls. Indeed both miR146a (Fig. 18) and 
miR155 (Fig. 16) were detectable in the second trimester of gestation in neurons 
of the stratum pyramidale (CA1-CA3) and in neurons of the DG, and their 
expression persisted at later prenatal and postnatal age. Similarly to controls also 
DS hippocampus showed miR146a in the VZ/SVZ (Fig. 18B,E). However, around 
mid-gestation we observed higher level of miR146a expression in astroglial cells 
within the hippocampal white matter, which persisted postnatally (Fig. 18G-H and 




Fig. 16. In situ hybridization of miR146a at different developmental ages in the hippocampus. (A) 
miR146a expression in the hippocampus at 13 GW. (B-D): miR146a at 22 GW, showing strong expression in 
the stratum pyramidale (CA1-CA3) and dentate gyrus; expression was also observed in the VZ/SVZ; insert in 
(D): co-localization with vimentin (Vim, red). (E): miR146a expression in the CA1 at 33 GW. (F-L) miR146a 
expression in the hippocampus at 1 day (F-H) 7 months (I) and 7 years (L; insert: high magnification of 
positive pyramidal neurons; CA1); insert in (G): co-localization with GFAPδ (red) in SVZ. Scale bar in (L). 




Fig. 17. In situ hybridization of miR155 at different developmental ages in control and DS hippocampus. 
(A-B): miR155 expression in the hippocampus at 22 GW (A) and at 1 day (B) with expression the stratum 
pyramidale (CA1-CA3) and dentate gyrus; (C-F): miR155 expression in the DS hippocampus at 22 GW (C-
D) 12 days (E) 6 months (F; insert, CA1) showing neuronal miR155 expression throughout the different 






Fig. 18. In situ hybridization of miR146a at different gestational ages in DS hippocampus. (A-C): 
miR146a expression in the DS hippocampus at 22 GW; (A): the hippocampus shows strong expression in the 
stratum pyramidale and dentate gyrus (insert shows positive glial cells in the white matter,alveus.); (B): 
expression was also observed in VZ/SVZ; (C): neuronal expression in CA1. (D-G): postnatal DS hippocampus 
at 12 days showing miR146a expression throughout the different hippocampal subfields (D); expression was 
also observed in VZ/SVZ (E); F: neuronal expression in CA1; (G): glial expression in the white matter 
(arrows); insert: co-localization with GFAP (red). (H): miR146a expression in the DS hippocampus at 15 years 




4.2.2 miR146a and miR155 expression in Down's syndrome hippocampus 
with Alzheimer’s disease pathology  
In the hippocampus of DS adult with AD pathology we observed, compared to 
controls, increased expression of miR146a and miR155 in astrocytes throughout 
the different hippocampal regions, particularly in regions with Aβ deposits (Fig. 
19, Fig. 20 and Fig. 21 A-B). Double labeling experiments confirmed the increased 
expression of both miR146a and miR155 in astrocytes of DS-AD patients (Fig. 19 
and Fig. 20). Focally co-localization with a microglial marker (HLA-DR) was 
observed for miR146a (Fig. 19F); we also observed expression of miR155 in blood 
vessels (Fig. 20E-G; co-localization with CD34). Similar patterns of expression 
has been observed in specimens of sAD (Fig. 21C-D). qPCR analysis of miR146a 
and miR155 in cortical specimens from DS-AS (early stages of AD) did not show 





Fig. 19. In situ hybridization of miR146a in adult hippocampus of control and Down's syndrome with 
Alzheimer’s disease pathology. (A) miR-146a expression in adult control hippocampus (insert: dentate 
gyrus ). (B-E) miR-146a expression in adult DS-AD hippocampus; in DS-AD increased expression was 
observed in cells with glial morphology throughout the hippocampus (arrows in CA4, C; CA1, D, white matter 
E, high magnification in insert a; insert in B shows dentate gyrus with increased expression in the molecular 
layer; insert b in E, amyloid plaque). (F) miR-146a was focally detectable in HLA-DR positive cells (red, 
arrows; around amyloid deposits, asterisks). (G): expression of miR-146a was observed in GFAP positive 





Fig. 20. In situ hybridization of miR155 in adult hippocampus of control and Down's syndrome with 
Alzheimer’s disease pathology. (A-B): miR-155 expression in adult control; neuronal expression is detected 
throughout the different hippocampal subfields (insert in A: dentate gyrus, DG; arrows in B pyramidal neurons 
of CA1). (C-G) DS-AD hippocampus with slightly increased expression in cells with glial morphology in the 
molecular layer of the DG (insert in C) and in CA1 (D); insert D, amyloid plaque. Panels (E-G) show 
expression in glial cells (arrows), neurons arrowheads and in endothelial cells (double arrowheads); insert (a) 
in € shows expression in GFAP positive cells (red) and insert (b) in E colocalisation with CD34in a blood 





Fig 21. Evaluation of miR-146a and miR-155 astroglial expression. (A-B): labeling score of miR146a (A) 
and miR155 (B) in controls and DS during development and adult DS with AD pathology. (C-D) labeling 
score of miR-146a (C) and miR-155 (D) in controls (n= 8), and sAD (n= 8, stage III); inserts in (C-D) show 




4.2.3 miR146a and miR155 expression in the Ts65Dn mice 
The expression of miR146a and miR155 was analyzed by q-PCR in the 
hippocampus and frontal cortex of Ts65Dn mice. miR146a expression showed an 
age-dependent decrease in both Ts65Dn and control euploid mice with lower 
expression at 6-18 months compared to 4-5 week old mice in hippocampus and 
cortex (Fig. 22A,D). miR155 showed a different age-depend changes in both 
Ts65Dn and control euploid mice with lower expression at 6-18 months compared 
to 4-5 weeks in hippocampus (Fig. 22B) and higher expression at 6-18 months 
compared to the 4-5 weeks in cortex (Fig. 22E). Two-way ANOVA analysis 
showed a contribution of age to the expression of both miR146a (cortex: F(3,41) 
= 24.08, P<0.0001; hippocampus: F(3,39) = 9.91, P<0.0001) and miR155 (cortex: 
F(3,39) = 45.2, P<0.0001; hippocampus: F(3,30) = 17.84, P<0.0001) and also the 
interaction between Ts65Dn trisomy and age (F(3,39) = 3.12, P=0.037). In both 
hippocampus and cortex, IL-1β showed higher level of expression in older animals 
(6-18 months compared to 4-5 weeks) and at 18 months we observed increased 
expression of IL-1β in Ts65Dn compared to control euploid mice (Fig. 22C,F). 
Two-way ANOVA analysis showed a significant contribution of age (cortex: 
F(3,41) = 33.85, P<0.0001; hippocampus: F(3,41) = 22.88, P<0.0001) and the 
interaction between Ts65Dn trisomy and age (cortex: F(3,41) = 8.00, P = 0.0003; 
hippocampus: F(3,41) = 3.13, P=0.36) to the expression levels of IL1β. The 
Bonferroni’s post-test showed a significantly increased expression of IL1β 
(P<0.001) in the Ts65Dn compared to control euploid mice at 18 months in the 
cortex only). Evaluation of the expression levels of downstream targets of 
miR146a (Irak1 and Traf6) and of miR155 (Ship1), showed higher expression of 
Traf6 in the cortex at 6-12 months compared to 4-5 week old mice (Fig. 22G). 
Two-way ANOVA analysis showed a significant contribution of age (F(3,41) = 
8.65, P=0.0001), of trisomy (F(1,41) = 5.75, P=0.21) and a significant interaction 
of age and trisomy (F(3,41) = 2.99, P=0.042) to the expression of Traf6 in the 
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cortex. The Bonferroni’s post-test showed significantly increased Traf6 expression 
in Ts65Dn compared to control euploid mice at 12 months (P<0.05). Expression 
of miR146a was negatively correlated (Spearman’s rank correlation coefficient r 
= -0.651, P=0.0008) with the downstream target Traf6 in the cortex in the Ts65Dn 
mouse (Fig. 22H). Ship1 showed a trend towards increased expression with 
increasing age in the hippocampus and cortex in both control euploid and Ts65Dn 
mice (Fig. 23). Two-way ANOVA analysis of the hippocampus samples showed a 
significant contribution of trisomy (F(1,41) = 4.11, P=0.049) and age (F(3,41) = 
14.67, P<0.0001) and the interaction between the two factors (F(3,41) = 5.94, 
P=0.002). Moreover, the Bonferroni’s post-test showed significantly increased 
expression (P<0.001) of Ship1 in the Ts65Dn compared to control euploid mice at 
6 months of age. Interestingly, in the cortex, although a significant contribution of 
age could be inferred (F(3,41) = 8.48, P=0.0002), there was neither an effect of the 
Ts65Dn trisomy nor an interaction effect. The Bonferroni’s post-test did not reveal 
any significant differences between Ts65Dn and control euploid mice. Two-way 
ANOVA analysis showed a significant interaction effect of age and Ts65Dn 
trisomy on the expression of Irak2 in the hippocampi of Ts65Dn and control 
euploid mice (F(3,41) = 6.88, P=0.0007 ). Bonferroni’s post-test showed a 
significant increase (P<0.05) in the expression of Irak2 in Ts65Dn compared to 
WT mice at 6 months age whereas a significant decrease (p<0.05) was observed at 
18 months. No difference was observed in the expression of Irak2 in the cortex of 
Ts65Dn compared to control euploid control mice (Fig. 23). Furthermore, no 
differences were observed in the expression of Cfh in the hippocampus and cortex 




Fig. 22. Expression of miR146a, miR155, IL-1β and the miR146a target Traf6 in the Ts65Dn mouse. (A-
G): qPCR of miR146a (A), miR155 (B), IL-1β (C) and Traf6 (G) in the hippocampus (A-C) and cortex (D-G) 
of the Ts65Dn mouse at 4– 5 weeks (n = 5) and 6 (n=6), 12 (n=6) and 18 months (n = 6) of age compared to 
age-matched euploid animals (n = 8 for 4-5weeks; n = 6 for 6, 12, 18 months). Data are expressed relative to 
the reference genes (geometric mean of Rnu6B and Rnu44 for the miRNAs and Tbp and Hprt for IL-1β and 
Traf6, respectively). The error bars represent standard error mean (SEM). Statistical significance : $ p<0.05 
showing the effect of Ts65Dn segmental trisomy; ### p<0.001 showing the effect of age and @@, P<0.01 
showing the interaction of Ts65Dn*age in a two-way ANOVA analysis. * P<0.05, ** P<0.01 and *** P<0.001 
show statistical significance assessed by the Bonferroni’s post-test (H): Scatter plots showing the significant 
negative correlation between miR146a and Traf6 in the cortex in the Ts65Dn mouse model; r = Spearman’s 




Fig. 23. Expression of Irak2, Cfh and Ship1 in the Ts65Dn mouse. (A-F): qPCR of Irak2, Cfh and Ship1 
in the hippocampus (A-C) and cortex (D-F) of the Ts65Dn mouse at 4 – 5 weeks (n = 5) and 6 (n=6), 12 (n=6) 
and 18 months (n = 6) of age compared to age-matched euploid animals (n = 8 for 4/5weeks; n = 6 for 6, 12, 
18 months). Data are expressed relative to the reference genes (geometric mean of Tbp and Hprt respectively). 
The error bars represent standard error of mean (SEM). Statistical significance : $, P<0.05 showing the effect 
of Ts65Dn segmental trisomy; ##, P<0.01, ###, P<0.001 showing the effect of age and @@, P<0.01 showing 
the interaction of Ts65Dn*age in a two-way ANOVA analysis. * P<0.05, ** P<0.01 and *** P<0.001 show 
statistical significance assessed by the Bonferroni’s post-test.  
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4.2.4 miR146a and miR155 expression in the APP-PS1 mice 
We analyzed the expression of miR146a and miR155 in the hippocampus of 
APP/PS1 mice using q-PCR (Fig. 24). At 3 months of age no difference in 
expression of miR146a and miR155 was seen between APP/PS1 and WT mice. 
APP/PS1 mice showed an increase in expression of both miR146a and miR155 at 
11-13 months of age as compared to both WT and 3 months-old APP/PS1 mice 
(Fig. 24A-B). The expression decreased for the two miRNAs at 19-21 months of 
age, however it remained higher than both WT and APP/PS1 mice at 3 months of 
age, although this difference was not statistically significant. Two-way ANOVA 
showed a significant contribution of the APP/PS1 mutations (miR146a: F(1,30) = 
5.90,P<0.05; miR155: F(1,30) = 4.95, P<0.05) and age (miR146a: F(2,30) = 
10.67,P<0.001; miR155: F(2,30) = 11.39, P<0.001) to the increased expression of 
both miRNAs, but no interaction of the two factors. The Bonferroni’s post-test 
showed increased expression of both miR146a and miR155 in APP/PS1 as 
compared to WT mice at 11-13 months of age (P<0.05). Increased expression of 
IL-1β was observed in the APP/PS1, compared to WT, at 11-13 months of age 
(P<0.01) persisting up to 19-21 months (P<0.001) (Fig. 24C). Two-way ANOVA 
showed a significant contribution of the APP/PS1 mutations (F(1,30) = 20.29, 
P<0.0001) and age (F(2,30) = 8.11, P=0.0015), and a significant interaction of the 
two factors (F(2,30) = 6.98, P=0.0032) to the increased IL-1β expression. A strong 
positive correlation (r=0.8769; P<0.0001) was observed between the expression of 
miR146a and miR155 within all the groups of mice (Fig. 24D). Positive correlation 
was also detected between both miR146a and miR155 and IL-1β (miR146, 
r=0.459; miR155, r=0.579; P<0.05; Fig. 24E-F). In addition, we also studied, by 
qPCR, the expression of Irak1 and Traf6 (targets of miR146a) and Ship1 (target of 
miR155) in APP/PS1 compared to WT mice. Irak1 and Traf6 showed a lower 
expression in APP/PS1 compared to WT mice already at 3 months of age (P<0.05 
and P<0.01 respectively). The expression further declined at 11-13 months of age 
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as compared to 3 months in both APP/PS1 and WT mice (Fig. 24G-H). Two-way 
ANOVA showed a significant contribution of age (Irak1: F(2,30) = 7.69, P=0.002; 
Traf6: F(2,30) = 21.06, P<0.0001) and of the APP/PS1 (Irak1: F(1,30) = 13.39, 
P=0.001; Traf6: F(1,30) = 10.81, P=0.0026) mutation to this decrease without any 
significant interaction. Ship1 (target of miR155) showed a time-dependent 
increased expression in the APP/PS1 mice, with significantly higher expression 
levels when compared to WT mice at 19-21 months of age (P<0.001). Two-way 
ANOVA demonstrated a strong effect of both age (Irak1: F(2,30) = 7.69, P=0.002; 
Traf6: F(2,30) = 21.06, P<0.0001) and APP/PS1 mutation (Irak1: F(1,30) = 13.39, 
P=0.001; Traf6: F(1,30) = 10.81, P=0.0026) (Fig 25). A strong negative correlation 
was observed between the expression levels of miR146a and Traf6 (Spearman’s 
rank correlation coefficient, r=-0.427, P=0.009) whereas Irak1 showed a trend 
towards negative correlation (r=-0.275) (Fig. 24I-J). No difference in expression 
of Irak2 and Cfh was observed in the hippocampi of APP/PS1 compared to control 
mice, although two-way ANOVA showed an age effect for Irak2 across the 




Fig.24.Expression of miR146a, miR155, IL-1β and the miR146a target Irak1 and Traf6 in the APP-PS1 
mouse. (A-C), (G), (H): qPCR of miR146a (A), miR155 (B), IL-1β (C), Irak1 (G) and Traf6 (H) in the 
hippocampi of APP-PS1 mice at 3 (n=6), 11-13 (n=6) and 19-21 months (n=6) compared to WT mice (n=6 
for 3, 11-13 and 19-21 months respectively). Data are expressed relative to the reference genes (geometric 
mean of Rnu6B and Rnu44 for the miRNAs and Tbp and Hprt for IL-1β, Irak1 and Traf6 respectively). The 
error bars represent standard error of mean (SEM). Statistical significance: $, p<0.05, $$$, P<0.001 showing 
the effect of APP-PS1 mutations, ## P<0.01 ### P<0.001 showing the effect of age, and @@, P<0.01 showing 
the interaction of APP-PS1*age in a two-way ANOVA analysis. *P<0.05, **P<0.01 and ***P<0.001 show 
statistical significance assessed by the Bonferroni’s post-test (D-F): Scatter plots showing significant 
correlation of miR146a with miR155 (D) and each miRNA with IL-1β expression (E-F). r = Spearman’s rank 
correlation coefficient; *P<0.05, **P<0.01, ***P<0.001. (I-J) Scatter plots showing the negative correlation 












































































































































































































































































































































































































































































4.2.5 miR146a and miR155 expression in Alzheimer’s Disease at different 
stages of the disease 
The expression levels of both miR146a and miR155 were analyzed, by qPCR, in 
hippocampal specimens of subjects with AD pathology covering Stages II-IV and 
healthy controls. The expression of miRNA146a (but not miR155) was increased 
in AD specimens (Braak stage IV), compared to controls (Fig. 26A-B). In these 
same specimens we observed the increased expression of IL-1β (Fig. 26C). The 
expression of both miR146a and miR155 showed a positive correlation (r=0.327, 
P=0.042 and r=0.466, P=0.002) with IL-1β (Fig. 26D-E). A negative correlation 
was observed between the expression levels of miR146a and its target Irak1 (r=-
0.355; p=0.027; Fig. 26G). No difference was observed in expression of Irak2 and 
Cfh whereas Ship1 (target of miR155) showed increased expression in AD 





Fig. 26. Expression of miR146a, miR155, IL-1β and Irak1 in sAD. (A-C), (F): qPCR of miR146a, miR155, 
IL-1β, Irak1 in A. Data are expressed relative to levels observed in control hippocampus (n=9, represented by 
the dashed line). The error bars represent standard error of mean (SEM). Statistical significance: * P<0.05, 
**P<0.01 relative to controls; ### P<0.001 Braak II vs Braak III. (D-E), (G): Scatter plots showing significant 
correlation of miR146a and miR155 with IL-1β expression and miR146a with its target Irak1. r = Spearman’s 

















































































































































































































4.3 Project 3: Impairment of BVR-A promotes brain insulin resistance in 
Alzheimer disease 
AD brain is characterized by an inadequate response to insulin, formerly known as 
BIR; it has been proposed a link between insulin resistance and cognitive 
dysfunction. However, the mechanisms that underlie this process are not fully 
elucidated. Since BVR-A represents an upstream inhibitory regulator of the insulin 
signaling cascade and because we previously demonstrated the OS-induced 
impairment of BVR-A in human AD brain, we hypothesized the involvement of 
BVR-A dysregulation in the onset of BIR. To this purpose we analyzed the age 
dependent changes of (i) BVR-A levels and activation, (ii) total amount of OS 
markers levels (PC, HNE, 3-NT), (iii) IR/IRS1 levels and activation in the 
hippocampus of 3xTg-AD mice. Furthermore, ad hoc experiments have been 
performed in SH-SY5Y cells to clarify the molecular mechanism(s) underlying 
changes observed in mice, focusing on the contribution of oxidative/nitrosative 
stress on insulin resistance. Finally, because mTOR is able to phosphorylate IRS1 
on critical Ser residues we investigated whether in our models (mice and cellular) 
insulin resistance can be associated with mTOR hyper-activation. 
4.3.1 Oxidative stress correlates with AD pathology in 3xTg-AD mice  
We evaluated by slot blot the changes of oxidative/nitrosative stress markers as 
total PC, total HNE adducts and total 3-NT levels in the hippocampus of 3xTg-AD 
mice at 3, 6, 12 and 18 months of age. We found a significant elevation of 3-NT 
levels since 6 months of age which further rises at 12 months and remains still 
elevated at 18 months in 3xTg-AD mice compared with age-matched WT mice 
(Fig. 28A). While PC and HNE levels showed a significant elevation only at 12 
and 18 months in 3xTg-AD mice of age compared with age-matched WT mice 
(Fig. 28A). In addition, age-associated changes related with the neuropathological 
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AD alterations occured in the same time-frame in the hippocampus of 3xTg-AD 
mice (Fig. 28B). The results obtained from the semi-quantitative analyses of Aβ 
and tau immunostaining showed a significant increase in Aβ in the hippocampus 
of 3xTg-AD mice at 6-month compared to age-matched WT mice, while no 
difference was found in tau immunoreactivity at the same age. At 12 months of 
age 3xTg-AD mice showed Aβ deposits and human tau-reactive neurons in the 
hippocampus. Finally, we found dense Aβ deposit and extensive human tau 
immunoreactivity in the 18 month old 3xTg-AD mice. None of these 
immunoreactive structures were detected in the WT brains (Fig. 28B). These 
results agree with previous results, which demonstrated, in 3xTg-AD mice brain, 





Fig. 28. Increased oxidative and nitrosative stress levels progresses with AD pathology in the 
hippocampus of 3xTg-AD mice. (A) PC levels (green squares), protein-bound HNE levels (blue triangles) 
and 3-NT levels (red dots) evaluated in the hippocampus of 3xTg-AD mice at 3 (n=6), 6 (n=6), 12 (n=6) and 
18 (n=6) months of age. Densitometric values shown are given as percentage of the age-matched WT mice 
(n=6/group), set as 100%. Means ± SEM of three replicates of each individual sample per group. *p˂0.05 and 
**p˂0.01 versus WT (Student's t-test). (B) Representative microphotographs (10 magnification, scale bar 100 
μm) and results obtained from the semi-quantitative analyses of Aβ and tau immunostaining from WT (n=3, 
white bars) and 3xTg-AD (n=3, black bars) mice. The data are mean ± SEM **p˂0.01 and ***p˂0.001 versus 




4.3.2 The impairment of BVR-A occurs early in the 3xTg-AD mice  
To evaluate the potential contribution of oxidative/nitrosative stress on BVR-A 
function, we analyzed the age associated changes of BVR-A protein levels, BVR-
A activation (pTyr-BVR-A) and 3-NT adducts on BVR-A protein (3-NT-BVR-A) 
from hippocampus of 3xTg-AD mice at different ages. Western blot analysis 
showed a significant reduction of BVR-A protein levels from 3 to 12 months in 
3xTg-AD mice in respect to WT mice, whereas a significant increase was observed 
at 18 months (Fig. 29). With regard to BVR-A activation we observed a significant 
early increase at 3 months followed by a reduction from 6 to 18 months. However, 
only at 6 months we observed a drastic reduction of pTyr-BVR-A, indeed at both 
12 and 18 months of age changes of pTyr-BVR-A levels did not reach the 
statistical significance (25% and 20%, respectively at 12 and 18 months of age, 
Fig. 29). In addition, in older 3xTg-AD mice (corresponding to the advanced stages 
of AD pathology) we observed that the altered BVR-A activation was coupled to 
a significant increase of 3-NT modifications, which peaked at 12 months, reaching 
150% in the 3xTg-AD mice compared to the relative control group (Fig. 29). 
Furthermore, we also investigated whether in 3xTg-AD mice the BVR-A reductase 
activity was impaired as reported in human AD brain [226]. We observed that the 
reductase activity was significantly reduced only at 12 months coincidently with 
the maximal increase of 3-NT-BVR-A at this time point, which is probably 
responsible of a general impairment of the protein (Fig. 29). These results highlight 
an early dysregulation of BVR-A either in terms of protein levels or activity, which 
worsen with the progression of AD pathology in these mice. Furthermore, the 
reduction of BVR-A activation coupled with increased total oxidative/nitrosative 
stress levels from 6 to 18 months suggests a probable link between these events in 




Fig. 29. Early impairment of BVR-A is observed during the progression of AD pathology in the 
hippocampus of 3xTg-AD mice. BVR-A (i) protein levels (red triangles), (ii) 3-NT modifications (green 
squares), (iii) Tyr phosphorylation (pTyr) (blue dots) and (iv) reductase activity (right columns) evaluated in 
the hippocampus of 3xTg-AD mice at (A) 3 (n=6), (B) 6 (n=6), (C) 12 (n=6) and (D) 18 (n=6) months of age. 
Left panels: western blot analyses. Representative bands are shown. Middle panels: densitometric analyses of 
wester blot protein bands. BVR-A protein levels were normalized per total protein load. 3-NT modifications 
and pTyr levels on BVR-A were normalized by using total BVR-A as loading control [215, 219]. 
Densitometric values shown are given as percentage of WT mice (n=6/group) set as 100%. Right panels: 
BVR-A reductase activity expressed as percent of WT mice (n=6/group) and evaluated as described in 
Materials and Methods. Means ± SEM, *p˂0.05 vs WT mice (Student's t-test).  
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4.3.3 BVR-A impairment leads to BIR in the 3xTg-AD mice  
To unravel the mechanisms through which the BVR-A dysregulation might impact 
the insulin signaling in AD, we evaluated changes with regard to IR and IRS1 
protein levels/activation in the hippocampus of 3xTg-AD mice at 3, 6, 12 and 18 
months of age. Through the evaluation of IR protein levels and activation 
[pIR(Tyr1662/1163)] as well as IRS1 protein levels and both activation 
[pIRS1(Tyr632)] and inactivation [pIRS1(Ser307)] in the hippocampus of 3xTg-
AD mice we highlighted two distinct phases (3-6 and 12-18 months). At 3 months 
of age we observed a significant reduction of IR protein levels (Fig. 30A) 
associated with a consistent elevation of IR activation (Fig. 30A) without 
significant changes of IRS1 protein levels or activation (Fig. 30A). At 6 months of 
age, both IR and IRS1 protein levels were reduced, while they appeared to be 
consistently activated (Fig. 30B). At 12 months of age, we observed a completely 
opposite scenario characterized by a reduction of IR protein levels and activation 
(Fig. 30C) together with a consistent increase of IRS1 inactivation (Fig. 30C), 
supporting the onset of the BIR state. Finally, at 18 months of age, 3xTg-AD mice 
are characterized by a persistent state of BIR as demonstrated by the elevated levels 
of IRS1 Ser307 phosphorylation (Fig. 30D). These results allow identifying 
different phases along the progression of AD pathology, which finally led to 
insulin resistance in the hippocampus of elder 3xTg-AD mice. Noteworthy, the 
strong reduction of BVR-A activation at 6 months of age is associated with the 
consistent increase of IRS1 activation; whereas the persistent impairment of BVR-
A at 12 months is associated with a clear inactivation of IRS1. These evidences 
are in agreement with our hypothesis suggesting that the lack of control exerted by 
BVR-A on IRS1 is firstly associated with IRS1 hyperactivation, which in turn 






Fig. 30. Hyper-activation of the insulin signaling precedes BIR in the hippocampus of 3xTg-AD mice. 
IR protein levels (blue diamonds), IR activation [pIR(Tyr1162/1163), green triangles], IRS1 protein levels 
(red triangles), IRS1 inactivation [pIRS1(Ser307), brown squares] and IRS1 activation [pIRS1(Tyr632), black 
dots] evaluated in the hippocampus of 3xTg-AD mice at (A) 3 (n=6), (B) 6 (n=6), (C) 12 (n=6) and (D) 18 
(n=6) months of age. Left panels: western blot analyses. Representative bands are shown. Right panels: 
densitometric analyses of western blot protein bands. Protein levels were normalized per total protein load. 
IR- and IRS1-associated phosphorylations were normalized by taking into account the respective protein 
levels and are expressed as the ratio between the phosphorylated form and the total protein levels: 
pIR(Tyr1162/1163)/IR, pIRS1(Ser307)/IRS1 and pIRS1(Tyr632)/IRS1. Densitometric values shown are 
given as percentage of WT mice (n=6/group) set as 100%. Means ± SEM, *p˂0.05, **p˂0.01 and ***p˂0.001 
vs WT mice (Student's t-test).   
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4.3.4 BVR-A impairment precedes TNF-α elevation in the 3xTg-AD mice  
Because TNF-α is known to inhibit BVR-A [241] we investigated whether reduced 
BVR-A protein levels could result from increased TNF-α level in the hippocampus 
of 3xTg-AD mice. To this purpose, we evaluated, by western blot analysis, the 
TNF-α protein levels in 3xTg-AD mice at 3, 6, 12 and 18 months of age (Fig. 31). 
In agreement with previous data [242, 243] we found a significant reduction of 
TNF- α levels from 3 to 12 months of age followed by a consistent increase in 
3xTg-AD mice with respect to WT at 18 months (Fig. 31). These results suggest 
that the reduction of BVR-A protein levels in 3xTg-AD mice is independent from 
TNF-α since it occurs before of the TNF-α elevation. 
 
Fig. 31. Age-associated changes of TNF-α protein levels in the hippocampus of 3xTgAD. TNF-α protein 
levels (blue dots) in the hippocampus of 3xTg-AD mice at 3 (n=6), 6 (n=6) and 12 (n=6) and 18 (n=6) months 
of age. Left panels: western blot analyses. Representative bands are shown. Right panels: densitometric 
analyses of western blot protein bands. TNF-α protein levels were normalized per total protein load. 
Densitometric values shown are given as percentage of WT mice (n=6/group) set as 100%. Means ± SEM, 
*p˂0.05 vs WT mice (Student's t-test).   
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4.3.5 BVR-A impairment and BIR in normal aging  
In order to identify whether BIR occurring during normal aging was associated 
with a dysregulation of BVR-A, we analyzed changes of IR/IRS1 protein levels 
and activation in light of the changes occurring with regard to BVR-A in the 
hippocampus of WT mice aged from 3 to 18 months. Western blot analysis showed 
a reduction of BVR-A protein levels both at 12 and 18 months; furthermore, it was 
associated to a reduction of BVR-A activation although this value did not reach 
statistical significance (Fig. 32A). At 18 months of age WT mice exhibited a 
significant increase of 3-NT-BVR-A (Fig. 32A) together with a significant 
decrease of BVR-A reductase activity (Fig. 33A), thus supporting a general age-
associated impairment of BVR-A. While with regard to TNF-α levels, the 
hippocampus of WT mice was characterized by a significant increase at 12 months 
followed by a consistent reduction at 18 months (Fig. 33C). The analysis of IR 
protein levels did not reveal any significant change (Fig. 32B), whereas with regard 
to IR activation we found a consistent increase from 3 to 12 months, followed by 
a fall at 18 months (Fig. 32B). A decrease of IRS1 protein levels together with a 
consistent IRS1 inactivation has been found with age (Fig. 32B). Indeed, while at 
6 months of age increased IR activation is not associated with IRS1 
hyperactivation, probably because BVRA is still functioning, at 12 and 18 months 
of age, reduced BVR-A protein levels and activation are associated with the 
inactivation of IRS1, and thus BIR. These results recall what we have observed in 
3xTg-AD mice and suggest that the impairment of BVR-A could represent a bridge 





Fig. 32. BVR-A impairment parallels BIR during normal aging in the hippocampus of WT mice. (A) 
BVR-A (i) protein levels (red triangles), (ii) 3-NT modifications (green squares) and (iii) Tyr phosphorylation 
(pTyr) (blue dots) evaluated in the hippocampus of WT mice at 3 (n=6), 6 (n=6), 12 (n=6) and18 (n=6) months 
of age. Upper panels: western blot analyses. Representative bands are shown. Lower panels: densitometric 
analyses of western blot protein bands. BVR-A protein levels were normalized per total protein load. 3-NT 
modifications and pTyr levels on BVR-A were normalized by using total BVR-A as loading control [215, 
219]. (B) IR protein levels (blue diamonds), IR activation [pIR(Tyr1162/1163), green triangles], IRS1 protein 
levels (red triangles), IRS1 inactivation [pIRS1(Ser307), brown squares] and IRS1 activation [pIRS1(Tyr632), 
black dots] evaluated in the hippocampus of WT mice at 3 (n=6), 6 (n=6), 12 (n=6) and 18 (n=6) months of 
age. Upper panels: western blot analyses. Representative bands are shown. Lower panels: densitometric 
analyses of western blot protein bands. Protein levels were normalized per total protein load. IR- and IRS1-
associated phosphorylations were normalized by taking into account the respective protein levels and are 
expressed as the ratio between the phosphorylated form and the total protein levels: pIR(Tyr1162/1163)/IR, 
pIRS1(Ser307)/IRS1 and pIRS1(Tyr632)/IRS1. Densitometric values shown are given as percentage of 3 
months-old mice set as 100%. Means7SEM, *p<0.05, **p<0.01 and ***p<0.001 vs 3 months; †p<0.05 and 





Fig. 33. Changes of BVR-A reductase activity, oxidative/nitrosative stress levels and TNF-α during 
normal aging in the hippocampus of WT mice. (A) BVR-A reductase activity expressed as units (U)/mL 
(n=6/group) as described in Materials and Methods. Means ± SEM, *p<0.05 vs 3-months old mice (ANOVA 
with post hoc Turkey t-test). (B) PC levels (green squares), protein-bound HNE levels (blue triangles) and 3-
NT levels (red dots) evaluated in the hippocampus of WT mice at 3 (n=6), 6 (n=6), 12 (n=6) and 18 (n=6) 
months of age. Densitometric values shown are given as percentage of 3 months old mice set as 100%. Means 
± SEM of three replicates of each individual sample per group. ***p<0.001 versus 3 months old mice 
(ANOVA with post hoc Turkey t-test). (C) TNF-α protein levels evaluated in the hippocampus of WT mice 
at 3 (n=6), 6 (n=6), 12 (n=6) and 18 (n=6) months of age. Upper panels: western blot analyses. Representative 
bands are shown. Lower panel: densitometric analyses of western blot protein bands. Protein levels were 
normalized per total protein load. Densitometric values shown are given as percentage of 3 months old mice 
set as 100%. Means ± SEM, *p<0.05 vs 3 months; †p<0.05 vs 6 months; ‡‡p<0.05 vs 12 months (ANOVA 




4.3.6 BVR-A impairment is associated with BIR in SH-SY5Y cells  
In order to demonstrate that BVR-A is effectively involved in the onset of BIR 
through an upstream inhibitory control on IRS1, we evaluated the BVR-A protein 
levels, pTyr-BVR-A as well as IR/IRS1 protein levels and activation in SH-SY5Y 
neuroblastoma cells under different conditions: normal insulin signaling, BIR and 
the over-induced insulin signaling. First, we investigated about the experimental 
condition to recreate in vitro the different state of insulin signaling. Thus in a 
preliminary set of experiments, we investigated whether insulin 0.1 µM 
administered for 24 h was able to activate the insulin signaling and whether the 
administration of additional increasing doses of insulin (0.1–5 µM for 1h) aimed 
to mimic insulin overexposure would promote BIR in our cellular model. As 
expected, insulin pre-treatment (0.1 µM for 24 h) promotes a significant increase 
of both IR and IRS1 activation (Fig. 34A and Fig. 35). By re-challenging pre-
treated cells with increasing doses of insulin (0.1–5 µM), we observed two 
opposite effects: increased IRS1 inactivation with insulin 0.1 µM and 0.5 µM (Fig. 
34A and Fig. 35) and increased IRS1 activation with insulin 5 µM (Fig. 34A and 
Fig. 35). Interestingly, none of these conditions were characterized by changes of 
BVR-A protein levels (Fig. 35). Therefore we investigated about the BVR-A 
activation levels because the activation, rather than the expression levels, would 
provide more information about the molecular mechanisms underlying insulin-
mediated effects. Thus we evaluated the BVR-A activation at 3 different 
conditions: normal insulin signaling (Ins 0.1 µM for 24 h), BIR (Ins 0.1 µM for 24 
h + Ins 0.1 µM for 1 h) and the over-induced insulin signaling (Ins 0.1 µM for 24 
h + Ins 5 µM for 1 h). As shown in Fig. 34A, normal insulin signaling is associated 
with a significant increase of pTyrBVR-A as expected, whereas BIR is 
characterized by a reduction of BVR-A activation. Surprisingly in condition of 
over-induced insulin signaling (Ins 5 µM for 1h) we observed a remarkable 
increase of BVR-A activation (Fig. 34A). Finally, we found that BIR also parallels 
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a significant reduction of the BVR-A reductase activity (Fig. 34D). All together 
these observations suggest that BIR is associated with a decreased BVR-A 
activation and that this phenomenon could be overwhelmed by higher doses of 











Fig. 34. BVR-A impairment is associated with BIR in SH-SY5Y neuroblastoma cells. (A) Insulin 0.1 µM 
for 24h induced both IRS1 activation (pIRS1(Tyr632), black dots) and BVRA activation (pTyr-BVR-A, blue 
dots) in SH-SY5Y neuroblastoma cells thus mirroring the physiological insulin signaling. Instead, pre-treated 
cells further treated with insulin (0.1 or 5 µM) for an additional hour to mimic insulin over-exposure, showed 
dose-dependent effects. Indeed, insulin 0.1 µM was associated with BIR (increased pIRS1(Ser307), brown 
squares) and BVR-A inactivation, whereas insulin 5 µM treatment by-passed BIR and was associated with 
increased activation of both IRS1 and BVR-A. *p<0.05, vs Ctr; †p<0.05, ††p<0.01 and †††p<0.001 vs Ins 
0.1 µM (ANOVA with post hoc Tukey t-test). (B) ONOO (50-500 µM) for 24 h dose-dependenlty promoted 
BIR (increased pIRS1(Ser307), brown squares) and BVR-A inactivation (reduced pTyr-BVR-A, blue dots) in 
SH-SY5Y neuroblastoma cells. Decreased pIRS1(Tyr632) was also observed. *p<0.05 and **p<0.01 vs Ctr 
(ANOVA ANOVA with post hoc Tukey t-test). (C) H2O2 50 µM for 24 h promoted BIR (increased 
pIRS1(Ser307), brown squares) and BVR-A inactivation (reduced pTyr-BVR-A, blue dots) in SH-SY5Y 
neuroblastoma cells. Increased pIRS1(Tyr632) was also observed, but IRS1 inactivation overcomes this effect. 
*p<0.05, vs Ctr (Student's t-test). (D) BVR-A reductase activity relative to A, B and C evaluated as described 
in Materials and Methods and expressed as percent of Ctr (n=3 independent cultures/group). Means ± SEM, 
*p<0.05 and **p<0.01 vs Ctr mice; †p<0.05, vs Ins 0.1 µM (ANOVA with post hoc Tukey t-test for Ins and 
ONOO- related experiments; Student’s t-test for H2O2 related experiment). For A, B and C: Upper panels: 
western blot analyses. Representative bands are shown. Lower panels: densitometric analyses of western blot 
protein bands. Protein levels were normalized per total protein load. IR- and IRS1-associated phosphorylations 
were normalized by taking into account the respective protein levels and are expressed as the ratio between 
the phosphorylated form and the total protein levels: pIR(Tyr1162/1163)/IR, pIRS1(Ser307)/IRS1 and 
pIRS1(Tyr632)/IRS1. pTyr levels on BVR-A were normalized by using total BVR-A as loading control [215, 
219]. Densitometric values shown are given as percentage of control cells (Ctr) set as 100%. Means ± SEM 








Fig. 35. Insulin over-exposure mimics brain insulin resistance (BIR) in SH-SY5Y neuroblastoma cells. 
SH-SY5Y cells were pre-treated with insulin 0.1 µM for 24 h to induce the activation of the insulin signaling. 
No significant changes have been observed for BVR-A protein levels with the tested doses (purple dots). 
Rather, insulin treatment was associated with a reduction of IR protein levels (blue diamonds) together with a 
consistent IR activation (pIR(Tyr1162/1163)/IR, green triangles). As expected, increased IR activation was 
coupled with increased IRS1 protein levels (red triangles) and IRS1 activation (pIRS1(Tyr632)/IRS1, black 
dots). No significant changes have been observed for BVR-A protein levels (purple dots). At the end of the 
24 h cells were rechallenged with increasing doses of insulin (0.1-0.5-1-5 µM) for an additional hour, to test 
the effects produced by insulin over-exposure. Additional insulin did not produce changes of IR protein levels 
or IR activation with regard to pre-treated cells, except at the dose of 5 µM, which promoted a further elevation 
of IR activation (pIR(Tyr1162/1163)/IR, green triangles). Instead, we observed a dose-dependent decrease of 
IRS1 protein levels together with modifications of its activation state. Moreover, a significant elevation of 
IRS1 inhibition (pIRS1(Ser307)/IRS1, brown squares) occurs at the doses of insulin 0.1 µM and 0.5 µM with 
respect to pre-treated cells. This effect was accompanied by a reduction of IRS1 activation 
(pIRS1(Tyr632)/IRS1, black dots), which rises-up at the dose of 1 µM to finally overcome BIR at the dose of 
5 µM. Upper panels: western blot analyses. Representative bands are shown. Lower panels: densitometric 
analyses of western blot protein bands. Protein levels were normalized per total protein load. IR- and IRS1-
associated phosphorylations were normalized by taking into account the respective protein levels and are 
expressed as the ratio between the phosphorylated form and the total protein levels: pIR(Tyr1162/1163)/IR, 
pIRS1(Ser307)/IRS1 and pIRS1(Tyr632)/IRS1. Densitometric values shown are given as percentage of 
control cells (Ctr) (n=3 independent cultures/group) set as 100%. Means ± SEM, *p<0.05, **p<0.01 vs Ctr; 




4.3.7 Increased oxidative and nitrosative stress levels promote BVR-A 
impairment and BIR in SHSY5Y cells  
Since oxidative and nitrosative stress elevation is associated with reduced BVR-A 
Tyr phosphorylation and BIR during both AD and normal aging in mice, we 
evaluated the effects of a nitrosative agent (ONOO, 50–500 µM for 24h) and a pro-
oxidant agent (H2O2, 0–50 µM for 24h) on SH-SY5Y cells with the aim to unravel 
whether oxidative/nitrosative stress could be a cause of the observed BVR-A 
impairment and BIR. We observed that the treatment with the nitrosative agent 
ONOO was associated with a significant elevation of IR protein levels at all the 
doses tested. Whereas only at the highest doses (250 and 500 µM) ONOO 
promotes a decrease of IR activation (Fig. 36), a significant increase of IRS1 
inhibition (Fig. 34B) and a reduction of BVR-A protein levels (Fig. 36) and 
activation (Fig. 34B). At all the doses tested the treatment with H2O2 did not 
produce changes of IR protein levels, while at both 10 µM and 50 µM an increase 
of IR activation, a decrease of IRS1 protein levels and an enhance of IRS1 
inhibition were observed (Fig. 37). Furthermore, 50µM H2O2 promoted a 
significantly increased of BVR-A protein levels (Fig. 37). Because the treatment 
with H2O2 at 50µM recreated the conditions previously observed in human AD 
brain and in 3xTg-AD mice, in which elevated OS levels co-exist with increased 
BVR-A protein levels and BIR, we then analyzed the BVR-A activation in this 
condition. Interestingly, we observed a consistent decrease of BVR-A Tyr 
phosphorylation (Fig. 34B). In accordance with findings in human and mice, these 
observations suggest that both ONOO and H2O2 at the highest doses promote a 
significant reduction of BVR-A reductase activity (Fig. 34D). These evidence 
clearly suggests that increased oxidative and nitrosative stress levels finally 
promote a reduction of BVR-A activation and BIR. Intriguingly, increased 
nitrosative stress levels could be among the mechanisms responsible for the 
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observed reduction of BVR-A protein levels and activation in the early phases of 
AD pathology, in 3xTg-AD mice. 
 
Fig. 36. Nitrosative stress promotes brain insulin resistance (BIR) in SH-SY5Y cells. To test whether 
nitrosative stress promotes BIR, SH-SY5Y cells were treated with increasing doses (50-500 µM) of 
peroxynitrite (ONOO-) for 24h. We observed a significant decrease of BVR-A protein levels (purple dots) 
with ONOO- 250 and 500 µM. Furthermore, ONOO- treatment promoted a significant elevation of IR protein 
levels (blue diamonds) along with a decreased IR activation (pIR(Tyr1162/1163)/IR, green triangles) at the 
highest doses. IRS1 protein levels (red triangles) are significantly elevated with ONOO- 50 and 100 µM, while 
we did not find significant changes with the highest doses. Upper panels: western blot analyses. Representative 
bands are shown. Lower panels: densitometric analyses of western blot protein bands. Protein levels were 
normalized per total protein load. IR-associated phosphorylation was normalized by taking into account the 
respective protein levels and is expressed as the ratio between the phosphorylated form and the total protein 
levels: pIR(Tyr1162/1163)/IR. Densitometric values shown are given as percentage of Ctr (n=3 independent 




Fig. 37. Oxidative stress promotes brain insulin resistance (BIR) in SH-SY5Y cells. To test whether 
oxidative stress promotes BIR, SH-SY5Y cells were treated with increasing doses (1-50 µM) of hydrogen 
peroxide (H2O2) for 24 h. BVR-A protein levels (purple dots) were significantly elevated in cells treated with 
H2O2 50 µM. We observed a significant increase of IR activation (pIR(Tyr1162/1163)/IR, green triangles) with 
both H2O2 10 and 50 µM, without changes of IR protein levels ( blue diamonds). IRS1 protein levels are 
consistently decreased at higher doses, while a significant increase of both activatory (pIRS1(Tyr632)/IRS1, 
black dots) and inhibitory (pIRS1(Ser307)/IRS1, brown squares) phosphorylation was observed. Despite of that, 
the extent of the inhibitory phosphorylation reach those of the activatory phosphorylation at the dose of 10 
µM to be finally prominent at the dose of 50 µM, thus indicating a condition of BIR [pIRS1(Ser307)/pIRS1(Tyr632) 
ratio expressed as percentage of control cells (Ctr) setted as 100% is: 95% (1 µM); 115% (5 µM); 108% (10 
µM) and 150% (50 µM)]. Upper panels: western blot analyses. Representative bands are shown. Lower panels: 
densitometric analyses of western blot protein bands. Protein levels were normalized per total protein load. 
IR- and IRS1-associated phosphorylations were normalized by taking into account the respective protein 
levels and are expressed as the ratio between the phosphorylated form and the total protein levels: 
pIR(Tyr1162/1163)/IR, pIRS1(Ser307)/IRS1 and pIRS1(Tyr632)/IRS1. Densitometric values shown are given as 
percentage of Ctr (n=3 independent cultures/group) set as 100%. Means ± SEM, *p<0.05, **p<0.01 vs Ctr 




4.3.8 Lack of BVR-A promotes BIR in SH-SY5Y cells  
Given that (i) BIR is associated with a reduced BVR-A activation and that (ii) both 
increased oxidative and nitrosative stress levels promote a decrease of BVR-A 
activation, we evaluated the effects produced on IR and IRS1 by BVR-A knock-
down in SH-SY5Y neuroblastoma cells. Interestingly, the silencing of BVR-A 
(siRNA) was associated with reduced IR protein levels and increased IR activation 
(Fig. 38). Despite of that, a clear inactivation of IRS1 was observed (Fig. 38). To 
note, the effects produced by insulin, in cells in which BVR-A was consistently 
silenced, differ from those produced under normal conditions. Indeed, we observed 
a dramatic increase of IRS1 inhibition after insulin treatment, which was even 
higher compared to siRNA alone (Fig. 38). These results indicate that reduced 
BVR-A activation, here mimicked by knocking-down the protein, leads to BIR, 
and that the effect normally produced by insulin would be shifted toward a 




























































































































































































































































































































































































































































































































































































































































































































































































4.3.9 BVR-A impairment causes BIR through mTOR 
Based on the fact that mTOR, once persistently stimulated, is able to phosphorylate 
IRS1 on Ser residues, including Ser307, critical for BIR development [244, 245] 
and because previous studies reported in AD the hyperactivation of mTOR [62, 
246-250]; we investigated whether also in our cellular model the BIR was 
associated with mTOR hyper-activation. To this purpose we evaluated mTOR 
protein levels and activation (measured by the levels of Ser2448 phosphorylation) 
in SH-SY5Y cells treated with insulin. We found that insulin treatment does not 
promote significant changes with regard to mTOR protein levels or activation (Fig. 
39A). Interestingly, by re-challenging pre-treated cells with increasing doses of 
insulin (0.1– 5 µM for 1 h), we further observed a significant increase of mTOR 
with insulin 0.1 µM and 0.5 µM and a subsequent decrease at the doses of 1 µM 
and 5 µM (Fig. 39A). These changes parallel either BIR or IRS1 activation and are 
consistent with changes of BVR-A activation in the same cells (Fig. 34A and Fig. 
35). Furthermore, to better clarify the impact of increased oxidative/nitrosative 
stress levels and BVR-A reduction on mTOR activation, we evaluated the effects 
produced by ONOO, H2O2 or BVR-A silencing in SH-SY5Y neuroblastoma cells. 
Interestingly, although ONOO and H2O2 treatments dose-dependently increased 
mTOR protein levels (Figs. 39B-C) they produced different outcomes on mTOR 
activation. Indeed, in accordance with previous findings [251], ONOO promoted 
a decrease of mTOR phosphorylation (Fig. 39B), whereas a consistent elevation 
of p-mTOR at Ser2448 was observed after the treatment with 50 µM H2O2 (Fig. 
39C). Surprisingly, in a subsequent set of experiments, the knock-down of BVR-
A was associated with a strong activation of mTOR (Fig. 40), while was further 
elevated in cells treated with both BVR-A siRNA and 0.1 µM insulin for 24 h (Fig. 
40). To note, H2O2-induced elevation of p-mTOR at Ser2448 is concomitant with 
the inactivation of BVR-A (Fig. 32C) and the increased IRS1 phosphorylation 
levels at Ser307 in the same samples (Fig. 34C). To check whether also in our mice 
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model BIR was associated with mTOR hyper-activation we then analyzed changes 
occurring both as effect of AD pathology and normal aging. We found that 3xTg-
AD mice are characterized by a significant elevation of p-mTOR (Ser2448) at 12 
months (Fig. 41A), which is consistent with increased pIRS1 (Ser307) levels 
observed at the same age (Fig. 30C). Furthermore, changes associated with normal 
aging highlight that despite a reduction of mTOR activity occurs from 3 to 12 
months, a significant increase at 18 months of age is evident with respect to both 
6 and 12 months (Fig. 41B). Although the extent of mTOR phosphorylation at 18 
months is still lower than those observed at 3 months of age, it is, however higher 
than those at both 6 and 12 months of age. Therefore, we think that the raise found 
at 18 months could be responsible at least in part of IRS1 inactivation. Indeed, in 
terms of percentage, this increase occurs at a similar extent of those observed in 
3xTg-AD mice or SH-SY5Y neuroblastoma cells characterized by BIR. Taken 
together, these findings denote that increased mTOR activation parallels either 
BVR-A impairment or insulin resistance in mice and cells, thus strengthening our 
hypothesis that dysregulation of BVR-A would lead to IRS1 hyperactivation, 
which is then turned-off by feed-back mechanism(s) including mTOR. Once again, 
the effects produced by nitrosative stress could be prominent in the early phase of 






Fig. 39. Aberrant mTOR activation is associated with a state of brain insulin resistance (BIR) in SH-
SY5Y cells overexposed to insulin or undergoing increased oxidative and nitrosative stress levels. mTOR 
protein levels (blue dots) and activation (p-mTOR(Ser2448)/mTOR, blue squares) in SH-SY5Y cells treated with 
insulin (A), ONOO- (B) or H2O2 (C) as previously described. For (A) and (B) Upper panels: western blot 
analyses. Representative bands are shown. Lower panels: densitometric analyses of western blot protein bands. 
For (C), left panels: western blot analyses. Representative bands are shown. Right panel: densitometric 
analyses of western blot protein bands. For (A), (B) and (C) protein levels were normalized per total protein 
load. mTOR phosphorylation was normalized per total mTOR protein levels and is expressed as p-
mTOR(Ser2448)/mTOR ratio. Densitometric values shown are given as percentage of control cells (Ctr) set as 
100%. Means ± SEM (n=3 independent cultures/group), *p<0.05 and **p<0.01 vs Ctr; ††p<0.01 and 




Fig. 40. Lack of BVR-A promotes mTOR hyper-activation in SH-SY5Y cells. mTOR protein levels (blue 
dots) and activation (p-mTOR(Ser2448)/mTOR, blue squares) were evaluated in SH-SY5Y cells knocked-down 
for BVR-A (BVR-A siRNA). Silencing BVR-A is associated with mTOR hyper-activation. Interestingly, 
insulin 0.1 µM further increases mTOR hyper-activation in cells lacking BVR-A. *p<0.05 and ***p<0.001 vs 
Ctr; †††p<0.001 vs Ins 0.1 µM (ANOVA with post hoc Tukey t-test). Left panels: western blot analyses. 
Representative bands are shown. Right panels: densitometric analyses of western blot protein bands. Protein 
levels were normalized per total protein load. mTOR phosphorylation was normalized per total mTOR protein 
levels and is expressed as p-mTOR(Ser2448)/mTOR ratio. Densitometric values shown are given as percentage 
of control cells (Ctr) set as 100%. Means ± SEM (n=3 independent cultures/group), *p<0.05 and **p<0.01 vs 





Fig. 41. Hyper-activation of mTOR parallels BIR both during AD and normal aging. (A) mTOR protein 
levels (blue dots) and activation [p-mTOR(Ser2448), blue squares] evaluated in the hippocampus of 3xTg-
AD mice at 3 (n=6), 6 (n=6), 12 (n=6), and 18 (n=6) months of age. Left panels: western blot analyses. 
Representative bands are shown. Right panels: densitometric analyses of western blot protein bands. Protein 
levels were normalized per total protein load. mTOR phosphorylation was normalized per total mTOR protein 
levels and is expressed as p-mTOR(Ser2448)/mTOR ratio. Densitometric values shown are given as 
percentage of WT mice (n=6/group) set as 100%. Means ± SEM, *p<0.05, vs WT mice (Student's t-test). (B) 
mTOR protein levels (blue dots) and activation [p-mTOR(Ser2448), blue squares] evaluated in the 
hippocampus of WT mice as effect of normal aging at 3 (n=6), 6 (n=6), 12 (n=6), and 18 (n=6) months of age. 
Upper panels: western blot analyses. Representative bands are shown. Lower panels: densitometric analyses 
of western blot protein bands. Protein levels were normalized per total protein load. mTOR phosphorylation 
was normalized per total mTOR protein levels and is expressed as p-mTOR(Ser2448)/mTOR ratio. 
Densitometric values shown are given as percentage of 3 months-old mice set as 100%. Means ± SEM, 





DS is caused by the anomalous presence of three copies of Chr 21 and 
characterized by a greatly increased risk of early-onset AD pathology. Indeed, after 
the age of 40 years, the majority of DS individuals develop a type of dementia with 
deposition of Aβ plaques and NFTs that are the most prominent and detrimental 
neuropathological change in AD brain. Inflammation and OS are known to occur 
in the brains of both AD and DS patients in response to the presence of Aβ plaques 
and NFTs [6, 13] and several studies demonstrated the involvement of OS and 
inflammation in accelerated senescence. In addition, the impairment in autophagy-
lysosome pathway, resulting in abnormal accumulation of proteins, play a critical 
role in both AD and DS pathology. Our recent study reported that the early 
accumulation of protein oxidative damage in human DS is concomitant with the 
alteration of mTOR/autophagy signaling. Furthermore, the development of BIR is 
considered a crucial event, impinging on mTOR/autophagy signaling, which 
contributes to the progression of AD-like pathology. Within this scenario, we 
focused our attention on the dysregulation of autophagy, insulin signaling and 
inflammation in DS and AD, human brain samples and animal models, to gain new 
insights in their role in the onset and progression of the neurodegenerative process. 
Finally, we propose that OS, as cause and/or consequence of increased free radical 
burden, represents the “leitmotif” shared by these altered pathways. In particular, 
a mutual relationship between redox homeostasis and mTOR/autophagy axis 
activity has been postulated. mTOR is a ser/thr protein kinase and involves in many 
cellular pathways that regulate neuronal development, synaptic plasticity, cellular 
aging and neurodegeneration processing. During embryonic development, mTOR 
signaling acts as a potent neuronal survival and division signal responding to 
growth factors. While in the adult brain, mTOR controls the synaptic plasticity, 
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neuronal polarity, neurotransmission and processes underlying memory and 
learning [252-256]. In the aged brain instead, mTOR is involved in the regulation 
of the proteostasis network because it is directly involved in the on/off switch of 
autophagy regulating phagophore formation [48]. Therefore, it is conceivable that 
the disturbance of mTOR signaling could lead to the alteration of autophagy and 
to the abnormal accumulation of protein aggregates, which characterizes both AD 
and DS pathology [42, 249, 252, 257, 258]. Increasing evidence suggests that the 
mTOR/autophagy axis plays a dual role in the cellular response to OS. Indeed, in 
vitro studies showed that increased levels of OS cause a reduction of mTOR 
activity, thus inducing the formation of autophagosomes in order to remove 
potential ROS-induced damage [259-261]. On the other hand, increased mTOR 
and reduced autophagy, due to aging and age-related disorders, can lead to ROS 
accumulation and the increase in oxidized proteins including the components of 
the protein degradative system, thus exacerbating the damage [57, 258, 262, 263]. 
AD and DS neuropathology are characterized by increased OS and in particular, 
our group demonstrated that DS cases reported increased oxidative damage to 
several components of autophagy and proteasome systems confirming a close 
connection between altered proteostasis network and increased OS [50, 264]. In 
addition, it has been demonstrated in DS brain the early mTOR hyperactivation 
coupled with the impairment of autophagy, insulin cascade and increased Aβ load, 
suggesting that all these events could trigger the appearance of AD symptoms in 
DS [62, 246, 252, 265]. In order to clarify the relationship between OS and 
mTOR/autophagy signaling, we analyzed the age-related accumulation of protein 
oxidation together with the integrity of the mTOR axis in Ts65Dn mice at different 
ages compared with age-matched euploid mice. In parallel, by blocking mTOR 
with rapamycin treatment in SH-SY5Ycells, we evaluated the effects of autophagy 
inhibition on protein oxidative damage. We hypothesize that the overexpression of 
human Chr 21 genes, such as Sod1, App or Bach1 (encoded on Chr 17 in mice), 
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might lead to increased ‘subchronic’ levels of OS in Ts65Dn mice [266, 267]. 
However, we show that despite the potential early genotype-dependent increase of 
OS in Ts65Dn mice the total levels of protein oxidation, indexed by both protein-
bound HNE and protein-bound 3-NT, start to rise at 6 months but become 
significantly increased only at 12 months compared with age-matched euploid 
mice. The analysis of mTOR expression, in Ts65Dn mice, shows an increase at 6 
months but unchanged levels at 12 months of age compared with age-matched 
euploid controls. Instead, the levels of mTOR phosphorylation on Ser 2448, which 
reflects the activation of mTOR, show increased levels at 6 and 12 months of age 
in Ts65Dn mice compared with age-matched euploid mice. These results support 
a genotype-dependent alteration of the mTOR pathway in Ts65Dn mice starting at 
6 months of age that persists at 12 months of age. Because mTOR inhibits the 
formation of autophagosomes, we evaluated LC3 II/I ratio demonstrating that 
increased mTOR phosphorylation is associated with a significant decrease in the 
LC3 II/I ratio in Ts65Dn mice both at 6 and 12 months of age compared with 
euploid mice. All together these results support that, despite the early alteration of 
the mTOR/autophagy pathway in Ts65Dn mice, protein oxidative damage 
becomes signiﬁcant only in old animals, suggesting that the accumulation of 
oxidative damage depend on the prolonged impairment of the mTOR/autophagy 
axis. To confirm our hypothesis, we evaluated the effect of rapamycin (mTOR 
inhibitor) on protein oxidation in SH-SY5Ycells H2O2-treated. Our data show that 
rapamycin administration decreased mTOR expression after 24, 48 and 72h when 
compared with control group, but only at 72h we measured a concomitant 
reduction of mTOR phosphorylation levels. Interestingly, the evaluation of 
autophagosome formation, as indexed by the LC3 II/I ratio, displayed an increase 
in the rapamycin treated group already after 48h compared to control. The 
evaluation of total protein oxidation, in the Rp group, showed a signiﬁcant 
decrease in protein bound 3-NT levels at 48 and 72h and a significant decrease in 
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protein-bound HNE levels at only 72h compared to St group. Overall, these data 
demonstrate that mTOR inhibition induces autophagosome formation and reduces 
the protein oxidative damage. This study provides further insights into the role of 
mTOR hyperactivation and autophagy reduction in the progression of 
neurodegenerative diseases characterized by the buildup of oxidized proteins such 
as AD and DS pathology. Hyperactivation of mTOR signaling has also been 
associated with increased OS and elevated inflammatory response. Among 
putative regulators involved in the inflammatory response we focalized our 
attention on miRNAs. 
miRNAs are post-transcriptional regulators of gene expression and increasing 
evidence support their involvement in neural development and neural function 
under physiological and pathological conditions [237-239]. In particular, miR146a 
and miR155 are two miRNAs associated with IL-1β pathway that differently 
modulate the inflammatory response astrocyte-mediated. miR146a acts as 
negative-inflammatory regulator by suppressing NF-κB transcriptional activity 
and sequentially blocks the TLR-signaling, while miR155 acts as pro-
inflammatory regulator through the inhibition of SHIP1, a negative regulator of 
TLR-signaling [186, 268]. Interestingly it has been reported the early upregulation 
of miR155 in 3xTg AD mice, in microglial and astrocytes exposed to Aβ [269], as 
well as the up-regulation of miR146a in human AD brain and in different AD 
mouse models [36, 37, 270]. Based on these observations we hypothesized that an 
inflammation-mediated dysregulation of both miR146a and miR155 in fetal brain 
(i.e. in DS) could contribute to development of neurobehavioral abnormalities, as 
well as, could contribute to age-related inflammatory neurodegenerative disorders, 
including AD pathology. Thus, in the present study we provide the first description 
of the expression pattern and cellular localization of both miR146a and miR155 in 
control and DS hippocampus during pre- and early postnatal development, as well 
as, in adults with DS-AD pathology. In order to provide supportive evidence of 
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age and pathology related dysregulation of miR146a and miR155, we evaluated 
the levels of these miRNAs, their putative targets and the levels of IL-1β in human 
hippocampus from sporadic AD and in Ts65Dn mice and APP/PS1 mice. We 
showed a similar developmental pattern of miR146a and miR155 expression in DS 
and control hippocampus with prenatal expression of miR146a in VS/SVZ and 
persistent neuronal expression at later prenatal and postnatal ages. However, at 
mid-gestation, we observed, higher level of miRNA146a expression in DS 
astroglial cells compared to control within the hippocampal white matter. Such 
astroglial expression persisted also postnatally. Since in a recent study using the 
same cohort, we could not detect significant differences in the number of astrocytes 
between DS patients and controls [271], and because miR146a is potently induced 
by IL-1β in astrocytes [186, 197], we think that this local upregulation of miR146a 
in DS hippocampus may be the result of a proinflammatory microenvironment 
involving IL-1β-mediated astroglial activation. Interestingly, a recent study 
identified miR146a as one of the miRNAs deregulated in autism spectrum 
disorders, as well as in patients with intellectual disability without autistic features, 
suggesting that miR146a upregulation could represent a common hallmark of 
different neurodevelopmental disorders [272]. Moreover, in vitro experiments 
indicate that an overexpression of miR146a may critically affect both neuronal and 
glial cells biology, resulting in an impaired neuronal dendritic arborization and 
increased astrocyte glutamate uptake [272]. We evaluated the expression of both 
miR155 and miR146a in Ts65Dn at different age (from 4-5 weeks to 18 months) 
in both cortex and hippocampus. While Keck-Wherley et al. [273] revealed 
increased expression (using qPCR) of miR155 in Ts65Dn hippocampus of 5 to 6 
weeks of age we failed to detect differences for both miR146a and miR155 at 4-5 
weeks but also in older Ts65Dn (6-18 months) and the target of miR155 (Ship1) 
was even increased in the Ts65Dn compared to control euploid mice at 6 months 
of age. We detected the upregulation of IL-1β mRNA in Ts65Dn at 18 months 
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compared to control euploid mice, indicating an increased activation of IL-1β 
pathway. While a previous study reported a reduction of IL-1β protein level in 
Ts65Dn hippocampus from 8 to 10 months of age [274], we didn’t detect 
significant differences in IL-1β expression between 4-5 weeks and 12 months in 
Ts65Dn compared to control euploid mice. Despite the higher level of IL-1β, we 
observed an age depend reduction of miR146a (hippocampus and cortex) and of 
miR155 (hippocampus) compared to young animals (4-5 weeks). In the cortex, the 
expression of miR146 was negatively correlated with its target Traf6, suggesting 
a modulation of the IL-1β pathway. The mechanisms underlying these age and 
region specific changes of miR146a and miR155 are still unclear and deserve 
further investigation. We observed a significant increase in expression of both 
miR146a and miR155 in APP/PS1 mice at 11-13 months of age as compared to 
both WT and APP/PS1 mice at 3 months. We also measured the increased 
expression of IL-1β in the APP/PS1 mice, compared to WT, confirming the 
activation of neuroinflammatory signals in this model [274]. Interestingly, a 
positive correlation was also detected between both miR146a, miR155 and IL-1β, 
in agreement with their known regulation via NF-B signaling [185, 186, 228, 268, 
275]. Moreover, we observed a negative correlation between the level of miR146a 
and the expression of its target Traf6. The more prominent deregulation of 
miR146a and miR155 observed in APP/PS1 AD model, compared to Ts65Dn DS 
model, may suggest the contribution of Aβ to the regulation of these miRNA, as 
supported by in vitro studies in glial cells [72, 276]. Accordingly, miR146a and 
miR155 were both upregulated in glial cells within the hippocampus of DS with 
AD pathology, particularly in the vicinity of Aβ deposits. In agreement with the 
involvement of miR155 in endothelial cell function and angiogenesis we also 
detected its expression in endothelial cells suggesting a role of miR155 in BBB 
dysfunction, which has been reported in AD [277, 278]. Furthermore, we reported 
the upregulation of miR146a in AD at late-stage and also showed a negative 
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correlation between miR146a and its target Irak1. This is in line with a recent 
study, which show the reduction of Irak1 mRNA levels in human astrocytes 
transfected with miR146a mimic after stimulation with IL-1β [186]. Another 
potential target of both miR146a and miR155 is the complement factor H (CFH), 
which acts as negative regulator of the innate immune and inflammatory response 
[279, 280]. Thus, the possible repression of CFH, has to be taken into account with 
respect to the interpretation of the ultimate effects of changes in the expression of 
miR146a and miR155. However, under our experimental conditions, we did not 
detect significant changes in the expression of CFH after overexpression or 
knockdown experiments targeting both miR146a and miR155 [186].  
An emerging link between peripheral metabolic disorder and AD has been 
proposed by recent epidemiological studies [199-202, 281, 282]. In particular, AD 
patients are characterized by impaired glucose metabolism and postmortem 
analyses in AD brain demonstrated an inadequate response to insulin known BIR. 
This condition is mainly due to reduced IR activation and increased levels of 
inhibitory phosphorylation of IRS1. However, the onset of BIR in AD is a matter 
still under debate. Because BVR-A represents an upstream regulator of the insulin 
cascade [214] and because we previously demonstrated that OS induces the 
impairment of BVR-A in human AD brain, we hypothesize that the OS-induced 
BVR-A dysregulation could be associated with the onset of BIR. The involvement 
of BVR-A in the insulin signaling is interesting for two main reasons: BVR-A is a 
direct target of IR kinase activity and once IR-phosphorylated is able to 
phosphorylate IRS1 on Ser inhibitory domains critical for insulin signaling [214] 
and (ii) BVR-A contains specific motifs in its sequence through which modulates 
IR kinase activity both negatively and positively [283]. Our work provides for the 
first time evidence (i) about a dysfunction of insulin signaling produced by the 
impairment of a member of the signaling itself, i.e., BVR-A, and (ii) on how the 
identified mechanism develops with AD pathology and normal aging. In order to 
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confirm our hypothesis and clarify the mechanisms underlying BIR we analyzed 
the age dependent changes of (i) BVR-A protein levels, (ii) BVR-A activation 
indexed by pTyr-BVR-A, (iii) total OS markers levels (PC, HNE, 3-NT) as well 
as (iv) IR/IRS1 levels and activation in 3xTg-AD mice. Furthermore, ad hoc in-
vitro experiments have been performed to decipher the contribution of increased 
oxidative/nitrosative stress on BVR-A impairment and insulin resistance. Finally, 
because mTOR is able to phosphorylate IRS1 we investigated also if the BIR could 
be associated with mTOR hyper-activation in both mice and in vitro model. 
Unexpectedly we found reduced BVR-A protein levels in the hippocampus of 
3xTg-AD mice aged from 3 to 12 months with respect to WT controls (Fig. 29A–
C). While, increased BVR-A protein levels have been found at 18 months of age 
(Fig. 28B) [284]. In agree with previous studies, the semi-quantitative analyses of 
Aβ and tau immunostaining demonstrated a gradually accumulation of Aβ and tau 
pathology in 3xTg-AD mice characterized by dense Aβ deposit and extensive 
human tau immunoreactivity at 18 months of age [240]. Furthermore, because 
TNF-α is known to inhibit BVR-A [241] we investigated whether reduced BVR-
A protein levels, observed from 3 to 12 months of age in 3xTg-AD mice, can result 
from increased TNF-α level. We found a significant reduction of TNF-α levels 
from 3 to 12 months of age followed by a consistent increase at 18 months in 3xTg-
AD mice with respect to WT (Fig. 31). All together these results suggest that the 
reduction of BVR-A protein levels, already evident at 3 months, seems to be a 
specific event, which occurs independently of TNF-α elevation (Fig. 31) and prior 
Aß and tau accumulation (Fig. 28B). In order to decode the potential contribution 
of oxidative/nitrosative stress to the alterations of BVR-A function, we evaluated 
the levels of oxidative/nitrosative stress markers and of pTyr-BVR-A in the 
hippocampus of 3xTg-AD mice at 3, 6, 12 and 18 months of age. This analysis 
allowed us to identify three different phases of BVR-A activation: a first phase at 
3 months of age characterized by an increased pTyr-BVR-A, a second phase at 6 
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months of age characterized by a drastic decrease of pTyr-BVR-A and a third 
phase from 12 to 18 months characterized by a consistent increase of 3-NT-BVR-
A. These results suggest that the reduction of BVR-A activation at 6 months is due 
to reduced phosphorylation on Tyr residues (Fig. 29B) rather than increased 3-NT 
modifications, which becomes consistent at 12 months (Fig. 29C). It is important 
to highlight that both phosphorylation and nitration reactions share the same Tyr 
residues and are mutually exclusive events [285] therefore one conceivable 
explanation for this control on BVR-A activation is that the increased total 3-NT 
levels observed at 6 months (Fig. 28A) affect redox sensitive signaling pathways, 
such as phosphorylation cascades [286]. Data obtained on cells treated with ONOO 
reinforced such hypothesis. Furthermore, we investigated whether in 3xTg-AD 
mice the BVR-A reductase activity was impaired as reported in human AD brain 
[226]. Interestingly, we observed a significant reduction of BVR-A reductase 
activity at 12 months, which coincides with increased levels of 3-NT modifications 
(Fig. 29), suggesting that increased oxidative/nitrosative stress levels promote the 
impairment of both BVR-A activities (reductase and kinase) with the progression 
of AD pathology. To unravel the mechanisms through which the BVR-A 
dysregulation might impact insulin signaling in AD, we evaluated changes with 
regard to IR and IRS1 protein levels/activation in the hippocampus of 3xTg-AD 
mice. We found the early increased activation of both IR and IRS1 from 3 to 6 
months followed by reduction of IR activation together with a consistent IRS1 
inactivation starting at 12 months of age (Fig. 30). These two phases are consistent 
with changes of BVR-A activation state suggesting that the lack of control exerted 
by BVR-A on IRS1 is primarily associated with IRS1 hyperactivation. This, in 
turn, leads to BIR probably through feedback mechanisms aimed to turn-off IRS1 
hyperactivity. Indeed, while at 3 months of age it is conceivable that IR hyper-
activation could be blunted by increased BVR-A activation, which would avoid 
IRS1 hyper-activation (Fig. 29A and Fig. 30A), at 6 months of age reduced BVR-
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A activation is associated with IRS1 hyper-activation (Fig. 29B and Fig. 30C–D). 
We propose that the period included between 6 and 12 months of age represents 
the time-frame for the switch from activated insulin signaling to BIR in the 
hippocampus of 3xTg-AD mice. Considering that insulin signaling positively 
modulate the synaptic plasticity and long-term potentiation (LTP) [287, 288], the 
dramatic decline of cognitive functions in 3xTg-AD from 6 to 12 months of age 
[284] correlates positively with our data on the impairment of the insulin signaling 
which mainly occurring in the same time-frame, supporting a role of defective 
insulin signaling in the decline of cognitive functions [284]. Surprisingly we 
observed that BIR occurs in the hippocampus of WT mice with normal aging and 
is associated with reduced BVR-A protein levels and with increased 3-NT 
modifications of BVR-A (Fig. 32A–B). Data about TNF-α levels only partially 
explain the reduction of BVR-A protein levels at 12 months of age, which precedes 
the appearance of the BIR at 18 months in WT mice (Fig. 32A–B). Indeed, whether 
increased TNF-α levels could contribute to BVR-A reduction at 12 months (Fig. 
32A and Fig. 33C)[241], reduced TNF-α levels at 18 months would not explain 
either the persistent reduction of BVR-A protein levels or the huge increase of 
IRS1 phosphorylation (Fig. 32A–B and Fig. 33C). With regard to 3-NT-BVR-A 
levels we observed a significant increase in WT mice at 18 months of age (Fig. 
34A) associated with a significant decrease of BVR-A reductase activity (Fig. 
44A). Essentially what emerges from our data on WT mice is that, during normal 
aging, BIR parallels with increased oxidative/nitrosative stress levels (Fig. 32B) 
and BVR-A impairment (Fig. 32A–B). These results strengthen the role of BVR-
A in the onset of BIR and we propose the impairment of BVR-A as a bridge 
connecting aging and AD. From a molecular point of view our cell-based 
experiments clearly highlight that insulin resistance is associated with a reduction 
of BVR-A activation and that oxidative and nitrosative stress promotes insulin 
resistance and BVR-A inactivation. Considering that in the brain the regulation of 
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glucose uptake and energy metabolism differs from peripheral tissues indeed the 
activation of insulin signaling cascade mainly exerts neurotrophic functions we 
demonstrated that silencing BVR-A in neurons promotes IRS1 inactivation and 
negatively impacts the effects produced by insulin itself (Fig. 38). We hypothesize 
that the persistent inactivation of BVR-A can initially sustain insulin signaling by 
IRS1 hyper-activation and subsequently promote BIR by unknown feedback 
mechanisms that turn-off IRS1-associated downstream effects. Because mTOR, 
once persistently stimulated, is able to phosphorylate IRS1 on Ser inhibitory 
domains, [244, 245] and because recent studies suggest the involvement of mTOR 
hyperactivation in AD [62, 246-250]; we propose mTOR as putative kinase 
implicated in BIR development causing IRS1 inhibitory phosphorylation. To this 
purpose we investigated in SH-SY5Y cells line whether insulin resistance and 
increased oxidative/nitrosative stress levels are associated with an aberrant 
activation of mTOR. We showed the aberrant activation of mTOR either following 
insulin over-exposure or H2O2 treatment. Instead, ONOO treatment was associated 
with a reduction of mTOR activation. Noteworthy, the silencing of BVR-A is 
associated with mTOR hyper-activation (Fig. 40). However, whether the observed 
increased mTOR activation is a direct effect of BVR-A inactivation or the results 
of the sustained activation of the insulin signaling has to be clarified. The fact that 
BVR-A could regulate mTOR activation [97] appear very fascinating and 
proposed by previous report that show high doses of biliverdin (the substrate of 
BVR-A) promote the activation of mTOR pathway [289]. However, because 
biliverdin does not directly regulate mTOR activation, and because biliverdin is 
known to inhibit BVR-A expression [241], our findings suggest that the effect of 
biliverdin on mTOR pathway can be an event secondary mediated by a down-
regulation of BVR-A. The idea that the reduction of BVR-A activity results in the 
hyper-activation of mTOR could represents one of the mechanisms responsible of 
IRS1 inactivation is further confirmed by data obtained in mice both during AD-
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like pathology and normal aging. Indeed, in 3xTg-AD mice mTOR hyperactivation 
occurs at 12 months of age (Fig. 41A), exactly when we observed significant IRS1 
inhibition (Fig. 30C), as well as in WT mice, but at 18 months of age (Fig. 32B 
and Fig. 41B). Taken together, these observations support our hypothesis that the 
persistent inactivation of BVR-A contributes to BIR in AD by mTOR 
hyperactivation. Furthermore, considering TNF-α as mediator of BIR in AD [290] 
and based on our results in 3xTg-AD mice, that showed increased levels of TNF-
α only at 18 months of age, we may hypothesize that the impairment of BVR-A 
coupled with the hyper-activation of mTOR are early events contributing to BIR. 
Finally, another interesting result is that the administration of high doses of insulin 
(5 µM) to SH-SY5Y cells, previously stimulated with insulin 0.1 µM, is able to 
overcomes insulin resistance (Fig. 34A) associated with the increased activation 




In this study we focused our attention on the dysfunction of molecular pathways 
including autophagy, insulin signaling and inflammation that are closely related 
with increased OS and that might be involved in the development of Alzheimer-
like dementia. A mutual relationship between redox homeostasis and 
mTOR/autophagy axis activity has been postulated and our results collected in 
Ts65Dn and SH-SY5Y neuroblastoma cell line support the idea that the defects of 
mTOR signaling contribute to the buildup of protein oxidative damage and that a 
protective role is played by autophagy in reducing protein oxidation. Further, a 
link between inflammation and OS exists and the hyperactivation of mTOR 
signaling has been associated with both increased OS and elevated inflammatory 
response. miR146a and miR155 are two inflammation-related miRNAs NF-κB-
inducible associated with IL-1β pathway. Increasing evidence supports the 
involvement of miRNAs in neural development and function under physiological 
and pathological conditions [237-239]. Interestingly, it has been reported the 
upregulation of miR155 and miR146a in AD brain and in different AD mouse 
models [280, 291]. Based on these observations we hypothesized that an 
inflammation-mediated dysregulation of both miR146a and miR155 in fetal brain 
(i.e. in DS) could contribute to development of neurobehavioral abnormalities as 
well as could contribute to age-related inflammatory neurodegenerative disorders 
including AD pathology. Our findings suggest a possible involvement of both 
miR146a and miR155 in the hippocampus during brain development and provide 
evidence of a dysregulation of these two immunomodulatory miRNAs in DS and 
AD pathology. In addition, the more prominent deregulation of miR146a and 
miR155 observed in APP/PS1 AD model, compared to Ts65Dn DS model, may 
suggest the contribution of Aβ to the regulation of these miRNA. Post-mortem 
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analyses in AD demonstrated BIR, due to reduced IR activation and increased 
inhibitory phosphorylation of IRS1, proposing a role for cognitive deficits. 
Because BVR-A is a direct target of IR kinase activity and once IR-phosphorylated 
is able to phosphorylate IRS1 on Ser inhibitory, and because we previously 
demonstrated that OS induces impairment of BVR-A in human AD brain, we 
suggest that BVR-A dysregulation could be associated with the onset of BIR. 
Furthermore, because mTOR, as BVR-A, is able to phosphorylate IRS1 on Ser 
inhibitory domains [244, 245] and because recent studies suggest the involvement 
of mTOR hyperactivation in AD [62, 246-250]; we investigated also if the BIR 
could be associated with mTOR hyper-activation. The results obtained suggest that 
the OS-induced inactivation of BVR-A initially sustain insulin signaling by IRS1 
hyper-activation. Such over-activation of the insulin signaling, for a time longer 
than normal, promote BIR by hyper-activation of mTOR that turn-off IRS1 hyper-
activity (Fig. 42).  
 
Fig. 42. Temporal profile of the events promoting BIR in the hippocampus 3xTg-AD mice. Proposed 
mechanism leading to BIR in AD. At 3 months of age the insulin binding to IR promotes IR phosphorylation 
on Tyr residues, which leads to a consistent activation of BVR-A. This latter, in turn, probably blunts IRS1 
hyper-activation thus allowing a still normal activation of the insulin signaling. At 6 months of age while IR 
appears to be still activated, BVR-A does not probably because increased 3-NT levels. Lacking BVR-A 
activity promotes IRS1 hyper-activation, which sustains the activation of the insulin signaling for a time 
perhaps longer than normal. Between 6 and 12 months of age, the further rise of the oxidative/nitrosative stress 
levels (PC, HNE and 3-NT) result in the oxidative stress-induced impairment of BVR-A, which contributes 
to maintain IRS1 hyperactive. IRS1 hyperactivation leads to the aberrant activation of mTOR, which through 
a feedback mechanism turn-off IRS1 thus leading to BIR. Finally, 18 months of age are characterized by the 
persistence of the same modifications observed at 12 months, which contribute to the maintenance of an BIR 
profile. Arrows, promotion; dotted lines, inhibition; Y, phosphor-Tyr residues; S, phospho-Ser residues; Y-
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